RUNX3 acts as an ocogene through a hedgehog-dependent pathway in selected human neoplasms by PEH BEE KEOW
  
 
RUNX3 ACTS AS AN ONCOGENE THROUGH A 















A THESIS SUBMITTED  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PATHOLOGY 







My gratitude goes to my supervisor, A/Prof. Manuel Salto-Tellez for his patient 
guidance and support throughout my Ph.D. study. I thank Prof Yoshiaki Ito for his 
kind advice and support. I also thank the Oncology Research Institute, currently 
known as Cancer Science Institute, and the Department of Pathology for supporting 
my Ph.D. work throughout. 
 
My sincere appreciation also goes to all my fellow colleagues and friends at CSI: Mei 
Xian, Ti Ling, Tada-san, Chee Wee, Sandy, Weiyi, Victor, Dawn, Norlizan, Feroz 
and Suhaimi, especially TK and Dominic for their kind assistance and constructive 
advice along my Ph.D. journey. I thank them for their friendship. I would also like to 
thank Dr Chan Shing Leng and Eileen, for their patience and guidance through my 
animal work. Many thanks also to the CSI administrative team (Selena, Deborah and 
Siew Hong) and the Department of Pathology administrative team (Rohana and 
Adeline) for their kind help. 
 
Last but not least, I would like to specially thank my fiancé, Teck Meng for his 
constant moral support and encouragement to make my Ph.D. journey a possible one. 
Endless gratitude also goes to my beloved parents and family members for their 



















TABLE OF CONTENTS   ii 
SUMMARY vi 
LIST OF TABLES   viii 
LIST OF FIGURES    ix 
LIST OF ABBREVATIONS xi 
  
CHAPTER 1  INTRODUCTION  1 
1. 1  Hedgehog Pathway 1 
 1.1.1  Hedgehog signaling pathway 1 
 1.1.2  SHH signaling pathway is dependent on primary cilium   
in mammals 
6 
 1.1.3  SHH signaling pathway during carcinogenesis 8 
  1.1.3.1  Genetics of basal cell carcinoma 9 
  1.1.3.2  Genetics of medulloblastoma 11 
 1.1.4  SHH-based therapeutics 14 
1.2  RUNX3 16 
 1.2.1  RUNX protein family 16 
  1.2.1.1  Nomenclature of RUNX 18 
  1.2.1.2  Evolutionary conservation of RUNX 20 
 1.2.2  Role of RUNX protein family 21 
  1.2.2.1  RUNX1 22 
  1.2.2.2  RUNX2 22 
  1.2.2.3  RUNX3 23 
 1.2.3  Gain or loss of RUNX genes in cancer 23 
 1.2.4  RUNX3 and TGF-β tumor suppressor pathway 26 





CHAPTER 2  HYPOTHESIS 30 
2.1  Original hypothesis: Preliminary data leading to the focus of this thesis 30 
2.2  Subsequent hypothesis: Core of the thesis 30 
  
CHAPTER 3  MATERIALS AND METHODS   32 
3.1  Materials 32 
 3.1.1  Primers 32 
 3.1.2  Commercial kit 35 
 3.1.3  Antibodies 36 
 3.1.4  General buffer preparation 36 
3.2  Methods 39 
 3.2.1  Collection and processing of human tissue samples 39 
  3.2.1.1  Human cancer specimens 39 
  3.2.1.2  Tissue microarray construction 40 
 3.2.2  Microscopy technique 43 
  3.2.2.1  Immunohistochemistry (IHC)   43 
 3.2.3  Cell lines and cell culture 44 
  3.2.3.1  Treatment of cells by cyclopamine 45 
 3.2.4  Sequencing of RUNX3 coding exons 46 
 3.2.5  siRNA transient transfection 47 
 3.2.6  Quantitative real-time PCR analysis 47 
 3.2.7  Protein isolation 48 
 3.2.8  SDS-PAGE and western blot analysis 49 
 3.2.9  Immunoprecipitation 49 
 3.2.10  Methylation-specific PCR 50 
 3.2.11  Promoter assay 50 
  3.2.11.1  Cloning of GLI1 promoter 50 
  3.2.11.2  Dual-luciferase reporter assay 51 
 3.2.12  Stable knockdown of RUNX3 53 
  3.2.12.1  Generation of lentiviruses 53 
  iv
 
  3.2.12.2  Lentiviral infection 55 
 3.2.13  MTS assay 56 
 3.2.14  Measurement of cell viability 56 
 3.2.15  Invasion assay and anchorage-independent growth  
assay in soft agar 
56 
 3.2.16  Xenografts in NOD/SCID mice 57 
 3.2.17  Chromatin immunoprecipitation (ChIP) 57 
 3.2.18  Statistical analysis 58 
  
CHAPTER 4  RESULTS 59 
4.1  RUNX3-SHH at a protein level: Is RUNX3 protein overexpression   
related to SHH signaling? 
59 
 4.1.1  Expression of RUNX3 in different skin malignancies 59 
 4.1.2  Expression of RUNX3 in normal skin and BCC 63 
 4.1.3  Expression of RUNX3 in medulloblastoma 65 
 4.1.4  Expression of β-catenin in normal skin and BCC 67 
 4.1.5  Western blot analysis of RUNX3 protein expression in 
normal and BCC cell lines 
69 
 4.1.6  Western blot analysis of RUNX3 protein expression in 
medulloblastoma cell lines 
70 
4.2  RUNX3-SHH: gene expression, methylation and sequencing evidence   71 
 4.2.1  Results of gene expression analysis in BCC clinical 
samples 
72 
 4.2.2  Results of mRNA gene expression in cell lines 74 
 4.2.3  RUNX3 mutation screening 76 
  4.2.3.1  Sequencing 76 
  4.2.3.2  RUNX3 methylation 76 
4.3  In SHH-related neoplasms, RUNX3 acts as an oncogene 79 
 4.3.1  Effects of stable knockdown of RUNX3 79 
 4.3.2  Soft agar assay 82 
 4.3.3  Nude mice assay 83 
4.4  The RUNX3-SHH interaction is at the level of GLI1 85 
 4.4.1  Regulation of RUNX3 by cyclopamine 85 
  v
 
 4.4.2  RUNX3 interacts with GLI1 in HTB-186 cells in vitro 87 
 4.4.3  RUNX consensus binding sequences in GLI1 promoter 87 
 4.4.4  RUNX3 is recruited to the binding sites on the promoters 
of GLI1 
89 
 4.4.5  Promoter assay 90 
  
CHAPTER 5  DISCUSSIONS 91 
  







Appendix 1 pGL3 VECTOR FOR CLONING OF PROMOTER 115 
Appendix 2 pRL-SV40 VECTOR  116 
Appendix 3 HUMAN RUNX3 cDNA  117 
Appendix 4 HUMAN GLI1 cDNA  118 
Appendix 5 SEQUENCE OF HUMAN GLI1 PROMOTER (1000 bp) 119 























RUNX3 is a cellular transcription factor and, as such is active in the nucleus (Katinka 
et al 1980, Tanaka et al 1982). In all adult solid cancers analyzed before the start of 
our work, RUNX3 acts as a tumor suppressor gene (Bae and Choi 2004) (down-
regulation is associated with tumorigenesis). RUNX3 is frequently inactivated by dual 
mechanisms of protein mislocalization (Ito et al 2005) and promoter hypermethylation 
(Kim et al 2005). Since RUNX3 is a relatively new gene discovered in the 1990s, its 
different roles in human pathology are not fully explored. Hence, I explored the effect 
of RUNX3 overexpression in Sonic Hedgehog (SHH) - related neoplasms.  
 
Through my screening, RUNX3 was up-regulated and active in basal cell carcinoma 
and desmoplastic medulloblastoma. Although SHH has a minimal role in most adult 
tissues, it is known to be activated in basal cell carcinoma (Botchkarev and Fessing 
2005) and medulloblastoma (Goodrich et al 1997). Silencing of RUNX3 with 
lentiviral shRNAs reduced cell proliferation and tumorigenesis in vitro and in vivo. In 
nude mice experiments, knockdown of endogenous RUNX3 in desmoplastic 
medulloblastoma cells significantly suppress tumorigenicity in nude mice. GLI1 was 
immunoprecipitated with RUNX3, indicating that endogenous RUNX3 interacts with 
endogenous GLI1 of the SHH signaling pathway. There are four RUNX consensus 
binding sequences in GLI1 promoter. Chromatin immunoprecipitation assay showed 
that RUNX3 is bound to the cognate RUNX3 binding site in the promoter region of 
GLI1.  
 
Altogether, these results showed that RUNX3 has an oncogenic activity in basal cell 
carcinoma and desmoplastic medulloblastoma. For the first time, GLI1 was identified 
  vii
 
as a novel downstream target of RUNX3 in the SHH signaling pathway. Strong 
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CHAPTER 1   INTRODUCTION 
 
1.1 Hedgehog Pathway 
 
1.1.1 Hedgehog signaling pathway 
The Hedgehog signaling pathway was originally identified in the fruit fly, Drosophila 
melanogaster. This pathway plays critical roles in cell proliferation, differentiation, 
and patterning in a range of tissues during animal development. It is activated by a 
secreted hedgehog protein of which three homologs have been identified in mammals 
- Sonic Hedgehog (SHH), Indian Hedgehog and Desert Hedgehog, of which SHH is 
the best studied. In skin, the SHH pathway is crucial for maintaining the stem cell 
population, and regulating the development of hair follicles and sebaceous glands. 
Although SHH has a minimal role in most adult tissues, it is known to be activated in 
basal cell carcinoma (BCC) (Botchkarev and Fessing 2005) and medulloblastoma 
(Goodrich et al 1997).  
 
In the absence of a signal, target gene transcription is turned off by the 
transmembrane protein Patched homologue 1 (PTCH1) which suppresses the 
activation of another transmembrane, G-protein-coupled receptor, Smoothened (SMO) 
(Figure 1) (Athar et al 2006). This suppression by PTCH1 inhibits the activation of 
the SHH signaling pathway (Kalderon 2005). The binding of SHH inactivates PTCH1 
with the help of coreceptors and relieves the suppression of SMO, leading to the 
posttranslational modification of the glioma (GLI) family of zinc-finger transcription 
factors. Subsequently, GLI activates the expression of downstream target genes which 
are involved in feedback regulation, cellular proliferation, maintenance of stemness, 
cell-fate determination, cellular survival, and epithelial-to-mesenchymal transition 
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(EMT). The list of the SHH target genes are summarized in Table 1. The downstream 
target genes which are involved in feedback regulation are GLI1 (Yoon et al 2002), 
PTCH1 (Yoon et al 2002), PTCH2 (Vokes et al 2007) and HHIP1 (Chuang and 
McMahon 1999, Vokes et al 2007). SHH signaling pathway regulates cell growth and 
proliferation by inducing MYCN (Hallikas et al 2006, Kenney et al 2003), CCND1 
(Kasper et al 2006), CCND2 (Yoon et al 2002), CCNE (Kenney and Rowitch 2000), 
FOXM1 (Schuller et al 2007, Teh et al 2002), CCNB1 (Schuller et al 2007) and 






Figure 1 SHH signaling pathway (Athar et al 2006). SHH ligand binds and 
inactivates PTCH1 which relieves the suppression of SMO, activating the
expression of downstream target genes. 
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SHH signaling also plays a role in regulating adult stem cells involved in maintenance 
and regeneration of adult tissues through JAG2 (Kasper et al 2006), FST (Eichberger 
et al 2008), GREM1 (Vokes et al 2008), BMP4 (Katoh and Katoh 2006, van den Brink 
et al 2001), WNT2B (Bonifas et al 2001), WNT5A (Bonifas et al 2001), PDGFRA (Xie 
et al 2001), BMI1 (Leung et al 2004, Liu et al 2006, Sangiorgi and Capecchi 2008), 
LGR5 (Barker et al 2007, Tanese et al 2008), CD44 (Chen et al 2007) and CD133 
(Clement et al 2007) and, as such, interacting with  most of the known putative stem 
cell biomarkers.  
 
SHH induces cellular survival through up-regulation of BCL2 (Regl et al 2004), 
CFLAR (Kump et al 2008), PRDM1 (Vokes et al 2008) and BMI1. BCL2, PRDM1, 
and BMI1 are directly up-regulated by SHH signals due to the existence of consensus 
GLI-binding motif within the promoter or enhancer regions (Vokes et al 2008). BCL2 
and CFLAR are anti-apoptotic. SHH signals protect cancer cells, especially cancer 
stem cells, from apoptosis through multiple apoptosis regulators. SHH signals induce 
EMT through multiple EMT regulators, such as SNAI1 (Li et al 2007), ZEB1 (Katoh 
and Katoh 2008), ZEB2 (Katoh and Katoh 2008), and FOXC2 (Hallikas et al 2006). 
SHH signals from epithelial cells indirectly induce BMP4 up-regulation in 
mesenchymal cells through up-regulation of Forkhead-box (FOX) family transcription 
factors FOXF1 (Madison et al 2009, Mahlapuu et al 2001) or FOXL1 (Hallikas et al 
2006, Madison et al 2009). Parathyroid hormone-related protein PTHLH (PTHrP) is 
up-regulated in breast cancer cells based on SHH signaling activation to promote 
osteolytic bone metastasis (Sterling et al 2006).  
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In mammals, three GLI proteins (GLI1, GLI2 and GLI3) are thought to exist in a 
complex with Suppressor of fused (SUFU) and possibly Costal-2 (COS2) and Fused 
(FU) homologues. COS2 and FU control SMO cell-surface accumulation by 
regulating SMO phosphorylation and that FU promotes SMO phosphorylation by 
antagonizing COS2 (Liu et al 2007). GLI1, GLI2, and GLI3 encode transcription 
factors that share five highly conserved tandem C2-H2 zinc fingers and a consensus 
histidine-cysteine linker sequence between zinc fingers (Ruppert et al 1988). The 
GLI1 and GLI3 proteins recognize a conserved GACCACCCA sequence in the 
promoters of target genes (Kinzler and Vogelstein 1990, Ruppert et al 1990), and 
GLI2 recognizes a nearly identical GAACCACCCA motif (Tanimura et al 1998). 
GLI1 and GLI2 can act as transcriptional activators, whereas GLI3 has both activator 
and repressor functions (Huangfu and Anderson 2006). GLI1 and GLI2 have 
overlapping and distinct transcriptional regulator properties, and overexpression of 

















Table 1 List of representative SHH target genes (Katoh and Katoh 2009) 
 
Function  Gene  Direct/Indirect  References 
Positive feedback GLI1 Direct target Yoon et al 2002 
PTCH1 Direct target Yoon et al 2002 
PTCH2 Direct target Vokes et al 2007 Negative feedback 
  
  HHIP1 Direct target 
Chuang and McMahon 
1999, Vokes et al 2007 
MYCN Direct target 
Hallikas et al 2006, 
Kenney et al 2003 
CCND1 Direct target Kasper et al 2006 
CCND2 Direct target Yoon et al 2002 
CCNE   Kenney and Rowitch 2000 
FOXM1   Teh et al 2002 







  CDC25B Indirect target Schuller et al 2007 
JAG2 Direct target Kasper et al 2006 
FST Direct target Eichberger et al 2008 
GREM1 Direct target Vokes et al 2008 
BMP4 
BMP7 Indirect target 
Katoh and Katoh 2006, van 
den Brink et al 2001 
WNT2B   Bonifas et al 2001 








  PDGFRA   Xie et al 2001 
BMI1   
Leung et al 2004, Liu et al 
2006, Sangiorgi and 
Capecchi 2008 
LGR5   
Barker et al 2007, Tanese 
et al 2008 




  CD133   Clement et al 2007 
BCL2 Direct target Regl et al 2004 Survival 
  CFLAR Direct target Kump et al 2008 
FOXC2   Hallikas et al 2006 
SNAI1   Li et al 2007 
TWIST2   Li et al 2007 





  ZEB2   Katoh and Katoh 2008 
FOXF1 Direct target 
Madison et al 2009, 
Mahlapuu et al 2001 
FOXL1 Direct target 
Hallikas et al 2006, 
Madison et al 2009 




  PTHLH   Sterling et al 2006 
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1.1.2. SHH signaling pathway is dependent on primary cilium in mammals 
The relatively recent discovery that SHH pathway signaling is dependent on the 
primary cilium, a cell organelle present on most mammalian cells, elucidated a new 
framework for this regulatory mechanism (Huangfu et al 2003, Huangfu and 
Anderson 2005, Liu et al 2005). It is therefore, possible that SHH signaling may also 
be altered in human syndromes caused by defects in cilia, including Bardet-Biedl 
syndrome, Kartagener syndrome, polycystic kidney disease and retinal degeneration 
(Pan et al 2005).  
 
Cilia can be grouped into three categories: motile cilia, nodal cilia and primary cilia. 
Motile cilia are usually present on a cell's surface in large numbers and beat in 
coordinated waves. Examples of motile cilia in vertebrates are those on the epithelial 
lining of the lung that move mucus, on ependymal cells lining brain ventricles that 
circulate cerebrospinal fluid, and on cells lining the oviducts and testes that move 
germ cells. Nodal cilia occur singly on cells of the embryonic node in vertebrates. 
They exhibit a rotational movement involved in the generation of leftward 
extraembryonic fluid flow and the establishment of morphogen gradients essential for 
left-right axis specification. Primary cilia are immotile and occur singly on most 
epithelial and stromal cells throughout the mammalian body, with the exception being 
differentiated cells of myeloid or lymphoid origin (Wheatley et al 1996). 
 
 In the absence of SHH, PTCH, located on the cell membrane at the base of the 
primary cilium, suppresses the activation of SMO, located on the membrane of 
intracellular endosomes, by blocking it from entering the cilium. GLI proteins are 
converted by proteosomes to the repressor form (GliR), which represses transcription 
  7
to the target genes (Figure 2). Signaling in the pathway is initiated by the SHH ligand 
binding to PTCH, which releases the inhibition of SMO. SMO migrates from the 
intracellular endosome to the cell membrane of the cilium. SMO is activated within 
the cilium and promotes the activation of GLI proteins (GliA). These enter the 
nucleus and promote the transcription of the SHH target genes. The bound 
SHH/PTCH complex is internalized from the cell surface into the interior of the cell 
and is destabilized or degraded (Huangfu et al 2003, Huangfu and Anderson 2005, 







Figure 2 SHH signaling in primary cilium (Caro and Low 2010). (A) In the 
absence of SHH, PTCH, located on the cell membrane at the base of the primary 
cilium, suppresses the activation of SMO. GLI proteins are converted by proteosomes 
to the repressor form (GliR), which represses transcription to the target genes. (B) 
Signaling in the pathway is initiated by the SHH ligand binding to PTCH, which 
releases the inhibition of SMO. SMO is activated within the cilium and promotes the 
activation of GLI proteins (GliA). These enter the nucleus and promote the 





1.1.3 SHH signaling pathway during carcinogenesis 
SHH signaling cascade is aberrantly activated in a variety of human cancers (Table 2). 
GLI1 is amplified more than 50-fold in a malignant glioma (Kinzler et al 1987). In 
addition, the GLI1 gene is also amplified in rhabdomyosarcoma (Khatib et al 1993); 
indeed the combined haploinsufficiency for the two tumor suppressor genes PTCH1 
and SUFU was suggested to be important for rhabdomyosarcoma (Tostar et al 2006). 
In oral squamous cell carcinoma, GLI2 is up-regulated (Snijders et al 2005). In 
transitional cell carcinoma (TCC), the major histological subtype of bladder cancer, 
loss of heterozygosity of PTCH1 occurs in >50% of TCC and only rare mutations 
could be detected in the retained PTCH1 allele (McGarvey et al 1998). HH-
interacting protein (HHIP), which functions as a negative regulator of the SHH 
pathway, is down-regulated in prostate cancers, compared with the corresponding 
normal tissues (Olsen et al 2004). On the other hand, the activation of the SHH 
pathway, through loss of SUFU, may be involved in tumor progression and 
metastases of prostate cancer (Sheng et al 2004). 
 
Table 2 Mechanisms of SHH signaling activation during carcinogenesis 
 
Type of Human 
Cancer Gene Mechanism References 
Glioma GLI1 Gene amplification Kinzler et al 1987 
GLI1 Gene amplification Khatib et al 1993 
PTCH1 Loss of function Tostar et al 2006 Rhabdomyosarcoma 
SUFU Loss of function Tostar et al 2006 
Squamous cell 
carcinoma GLI2 Gene amplification Snijders et al 2005 
Bladder cancer PTCH1 Loss of function McGarvey et al 1998 
HHIP1 Transcriptional down-regulation Olsen et al 2004 Prostate cancer 
SUFU Loss of function Sheng et al 2004 
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1.1.3.1 Genetics of basal cell carcinoma 
Basal cell carcinoma (BCC) is the most common form of low grade skin malignancy 
in many parts of the world. BCCs are slow growing tumors that recur frequently, but 
rarely metastasize. They are usually found on the face, head and neck. Surgical 
resection is usually curative, but leaves a permanent scar, restricts muscle movement 
and is not a preventive measure. It is estimated that one in three born in the USA after 
1994 will have at least one BCC in their lifetime (Einspahr et al 2002). An analysis of 
the Singapore Cancer Registry reveals that in Singapore, the incidence rate of BCC 
increases 3% annually (Koh et al 2003). 
 
The genes in the SHH pathway have a variety of loss of functions or activating 
mutations in BCCs (Table 3). The GLI transcription factors mediate the SHH signal in 
development and carcinogenesis. BCC can be caused by overexpression of either 
GLI1 (Eichberger et al 2006) or GLI2 (Eichberger et al 2006, Grachtchouk et al 2000). 
Majority of BCCs occur sporadically, but there is one inherited disorder in which 
patients have an increased susceptibility to developing BCCs. This is the Gorlin 
syndrome, also known as basal-cell nevus syndrome or nevoid basal-cell carcinoma 
syndrome (Gorlin 1987). Gorlin syndrome is an autosomal dominant disorder that 
predisposes to BCCs of the skin, ovarian fibromas, and medulloblastomas. Using 
family-based linkage studies of kindreds with Gorlin syndrome, the locus carrying the 
causative mutant gene was mapped to human chromosome 9q22 (Gailani et al 1992) 
and then to the PTCH1 gene. Loss of heterozygosity at this chromosomal location 
implies that the gene is homozygously inactivated and normally functions as a tumor 
suppressor. Thus, in the BCC paradigm PTCH1 functions as a classic tumor 
suppressor gene (Hahn et al 1996, Johnson et al 1996). 
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Approximately 90% of sporadic BCCs have identifiable mutations in at least one 
allele of PTCH1 (often loss of the portion of chromosome 9q harbouring PTCH1) 
(Aszterbaum et al 1998, Gailani et al 1996), and an additional 10% have activating 
mutations in the downstream SMO protein (Reifenberger et al 2005, Xie et al 1998), 
which presumably render SMO resistant to inhibition by PTCH1. Although similar, 
PTCH2 undergoes alternative splicing and is up-regulated in BCCs (Zaphiropoulos et 
al 1999). The gain of function of SHH in the epidermis is sufficient to induce BCCs 
of the skin. These could arise from hair follicles as SHH signaling pathway 
participates in follicular development (Oro et al 1997). Loss of function mutations in 




Table 3 Mutations in the SHH signaling pathway in BCCs 
 
Type of Human 
Cancer Mutation Mechanism References 
GLI1 Gain of function Eichberger et al 2006 
GLI2 Gain of function Eichberger et al 2006, Grachtchouk et al 2000 
PTCH1 Loss of function Aszterbaum et al 1998, Gailani et al 1996 
PTCH2 Loss of function Zaphiropoulos et al 1999 
SMO Gain of function Reifenberger et al 2005, Xie et al 1998 
SHH Gain of function Oro et al 1997 
Basal cell 
carcinoma 
SUFU Loss of function Reifenberger et al 2005 
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1.1.3.2. Genetics of medulloblastoma 
Medulloblastoma is the most common type of malignant brain tumor arising in the 
cerebellum in childhood. Medulloblastoma is part of the family of tumors known as 
primitive neuroectodermal tumors (PNET), which are highly malignant, small round 
blue cell tumors of the central nervous system. The current treatment of patients with 
medulloblastoma is with surgical removal of the tumor, adjuvant radiation therapy 
and chemotherapy. According to data from Singapore Children's Cancer Registry, 
brain tumors make up about 17% of all childhood cancers in Singapore (Chan et al 
2007). Medulloblastoma or primitive neuroectodermal tumor is the most common 
type of brain tumor, comprising 40.7% of all brain tumors diagnosed in children. The 
incidence of medulloblastoma is 0.73 cases per 100,000 per year in Singapore (Chan 
et al 2007).  
 
Histological subtypes of medulloblastoma have been described and include the 
desmoplastic variant and the conventional large cell variant (Friedman et al 1991). 
The desmoplastic variant is composed of islands of larger, pale cells in a sea of 
smaller, more typical medulloblastoma cells. In addition, an abundant collagenous 
matrix is present. In the conventional large cell variety, the cells are larger and more 
pleomorphic. Microscopically, the tumor is invasive at its edges, although penetration 
into the surrounding cerebellum is somewhat limited. Desmoplasia has been related to 
a worse prognosis in children, to a better prognosis in adults, and to no difference in 
survival (Friedman et al 1991, Katsetos and Burger 1994). At present, there is no 
consensus regarding prognosis and its correlation to histology (Rorke et al 1997).  
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The SHH pathway regulates the growth and patterning of the cerebellum (Dahmane 
and Ruiz i Altaba 1999). PTCH is expressed by neuronal precursors in the external 
granular cell layer (EGL) in the developing cerebellum. SHH is produced by Purkinje 
neurons that lie beneath the EGL. The blocking of SHH signaling in vivo leads to 
hypoplastic cerebella in which granule neurons are greatly reduced or absent. These 
results strongly suggest that EGL neuronal precursors are stimulated to divide by 
SHH signaling. The factors that lead to differentiation and migration of the post 
mitotic neurons are not clear at this time, although b-FGF has been shown to block the 
SHH induced proliferation of EGL cells in vitro. Figure 3 summarizes role of the 
SHH pathway in the development of the cerebellum (Raffel 2004).  
 
Like the BCCs, the genes in the SHH pathway have a variety of loss of functions or 
activating mutations in medulloblastomas (Table 4). miR-324-5p microRNA (miRNA) 
is involved in translational repression of GLI1 protein, therefore down-regulation of 
miR-324-5p leads to GLI1 overexpression in medulloblastoma (Ferretti et al 2008). 
Medulloblastoma can also be caused by overexpression of GLI2 (Northcott et al 
2009). SMO is overexpressed due to down-regulation of miR-125b or miR-326 
mRNAs in medulloblastoma (Ferretti et al 2008), because miR-125b and miR-326 are 
involved in translational repression of SMO. PTCH receptors are inactivated due to 
point mutation of PTCH1 gene (Raffel et al 1997) and also due to point mutation of 
PTCH2 gene (Smyth et al 1999) in medulloblastoma. Loss of function mutations of 












Figure 3 The role of SHH in cerebellar development (Raffel 2004). Granule 
neuronal precursors (A – D) migrate tangentially from the rhombic lip and may use 
the SHH pathway in transient autocrine manner. Purkinje neurons and later-born 
Bergmann glia (B) derive from the ventricular zone and migrate toward the EGL. 
SHH from the Purkinje neurons induces Bergmann glia maturation (C). In the later 
EGL, granule neuronal precursors proliferate in the outer zone, utilizing SHH secreted 
from Purkinje neurons. At the same time, mature glia send their extensions toward the 
inner EGL (D) and these or other cortical cells may provide factors that promote the 
differentiation if granule neurons, antagonizing the effects of SHH. Granule cells then 
migrate on glial fibers across the molecular and Purkinje layers to form the IGL. 




Table 4 Mutations in the SHH signaling pathway in medulloblastomas 
 
Type of Human 
Cancer Mutation Mechanism References 
GLI1 miRNA dysregulation Ferretti et al 2008 
GLI2 Amplification Northcott et al 2009 
PTCH1 Loss of function Raffel et al 1997 
PTCH2 Loss of function Smyth et al 1999 
SMO miRNA dysregulation Ferretti et al 2008 
Medulloblastoma 




1.1.4. SHH therapeutics 
Various compounds targeted to the SHH signaling cascade have been developed 
(Table 5). Robotnikinin is a small molecule SHH signaling inhibitor binding to 
extracellular SHH protein (Stanton et al 2009). The steroidal alkaloid cyclopamine 
has both teratogenic and anti-tumor activities by binding to the heptahelical bundle of 
SMO (Chen et al 2002) and inhibits its activity by inhibiting SMO's activation step 
within the primary cilium (Wang et al 2009). Cyclopamine has poor water solubility 
and acid lability which hinders its utility as an easily administrable drug (Cooper et al 
1998, Incardona et al 1998). Therefore, several derivatives such as KAAD-
cyclopamine, with higher affinity and better bioavailability have been developed 
(Taipale et al 2000).   
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SANT1, SANT2, SANT3, SANT4 and HhAntag are small molecule SHH signaling 
inhibitors targeted to SMO (Chen et al 2002, Romer et al 2004, Yauch et al 2008). 
CUR-61414 shows good SHH pathway inhibitory effects in Ptch1 null cells and 
mouse BCC explants in vitro (Williams et al 2003) but a topical formulation, based on 
CUR-61414, entered a phase I clinical trial in 2005 for BCC and was halted due to 
low efficacy. GDC-0449 identified by Genentech, entered phase I clinical trials in 
2007 for patients with locally advanced or metastatic solid tumors (Trial identifier # 
NCT00607724). GANT58 and GANT61 are small molecule SHH signaling inhibitors 
targeted to GLI1 activator (Lauth et al 2007). 
 
 
Table 5 A selection of SHH targeted therapeutics 
 
Target Compound References 
SHH Robotnikinin Stanton et al 2009 
Cyclopamine Cooper et al 1998, Incardona et al 1998 
KAAD-Cyclopamine Taipale et al 2000 
SANT-1, SANT-2, SANT-3 and 
SANT-4 Chen et al 2002 
HhAntag Romer et al 2004, Yauch et al 2008 
CURR61414 Williams et al 2003 
SMO 
 
GDC-0449 Trial identifier # NCT00607724 






The delineation of the SHH signaling pathway, the recognition that aberrant SHH 
signaling may lead to certain cancers, and the understanding of the pathway inhibition 
have led to the development of potential therapeutic agents as targeted therapy in 
cancer. Through a better understanding of the role that RUNX3 play in the SHH 
signaling pathway, novel approaches may emerge whereby unregulated 
overexpression of the SHH signaling pathway could be attenuated as an effective 
therapy in patients with numerous cancers. Further development of SHH inhibitors for 
BCC could convert this disease from a primarily surgically treated disease to a 
medically treated disease, creating more options for patients, especially those with 





1.2.1 RUNX protein family 
The polyomavirus enhancer-binding protein 2 (PEBP2/CBF) is a heterodimeric 
transcription factor, which consist of α and β subunit (Ito 1999). The α subunit is 
encoded by RUNX genes and is called the polyomavirus enhancer-binding protein 2 
(PEBP2)α/core binding factor (CBF)α of the Runt domain transcription factors. There 
are three mammalian runt-related genes, namely RUNX1 (PEBP2αB/CBFα2/AML1) 
(Bae et al 1993), RUNX2 (PEBP2αA/CBFα1/AML3) and RUNX3 
(PEBP2αC/CBFα3/AML2) (Bae et al 1995). All three factors contain an 
evolutionarily conserved region, termed the Runt domain (Kagoshima et al 1993, 
Ogawa et al 1993), which is responsible for binding to DNA and for 
heterodimerization with the β subunit. The β subunit lacks both intrinsic DNA-
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binding activity and a nuclear localization signal. RUNX proteins alone are unstable, 
as they are subjected to ubiquitination followed by proteolytic degradation by 
proteasome enzymes (Huang et al 2001). Hence, the heterodimer structure prevents 
ubiquitination and thus, stabilizing RUNX proteins. Together with the PEBP2β 
subunit, RUNX transcription factors can act as activators or repressors of transcription, 
depending on the context which they bind DNA (Canon and Banerjee 2003). 
 
The three-dimensional crystal structure of the Runt domain, heterodimerized with the 
134-amino acid region of PEBP2β and bound to DNA, was determined by various 
groups by NMR and crystallography (Berardi et al 1999, Nagata et al 1999, Tahirov et 
al 2001) and is shown in Figure 4. RUNX heterodimers are relatively weakly acting 
transcriptional regulators (Perry et al 2002). Due to the low expression level of RUNX 
proteins, subcellular localization of RUNX proteins has been studied largely using 
exogenously expressed RUNX proteins in fibroblasts and leukemic cells. By 
immunocytochemistry, RUNX proteins are localized in the nucleus, whereas 

















Figure 4 Crystal structure of the Runt domain heterodimerized with the 134 





1.2.1.1. Nomenclature of RUNX 
The Runt-related (RUNX) family of transcription factors was first discovered by 
virologists. An investigation of the restriction of viral growth in embryonic carcinoma 
cells by polyomavirus, led to the discovery and identification of an important cellular 
transcription factor, the polyomavirus enhancer binding protein 2 (PEBP2) (Katinka 
et al 1980, Tanaka et al 1982). Further purification and cDNA cloning revealed that 
PEBP2 consisted of two subunits, a DNA-binding α subunit (PEBPα) and a non-
DNA-binding β subunit (PEBPβ) (Kamachi et al 1990). RUNX genes encode the α 
subunits called the polyomavirus enhancer-binding protein 2 (PEBP2)α/core binding 
factor alpha (CBFα) of the Runt domain transcription factors. 
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The runt-domain transcription factors RUNX1, RUNX2 and RUNX3 were assigned 
many different names by different laboratories. Based on the genetic studies of 
leukemia-related chromosomal translocations, the designation acute myelogenous 
leukemia (AML) factors (i.e. AML1, AML2 and AML3) were derived. The sequence 
specific DNA-binding proteins that interact with the enhancers of retroviruses were 
characterized as Core-binding factor alpha (CBFα). PEBP2 was named after the 
murine cDNAs polyoma enhancer-binding proteins. Other aliases, such as nuclear 
matrix protein 2 (NMP2), osteoblast-specific complex (OBSC) and osteoblast-specific 
factor 2 (OSF2) were also generated.  In November 1999, the Nomenclature 
Committee of the Human Genome Organization (HUGO) adopted the use of the term 
‘RUNX’ to refer to the genes encoding the runt-related proteins, also an abbreviation 
for the term ‘runt-related protein’ (van Wijnen et al 2004). The mammalian RUNX 
genes and their synonyms as well as their locus are as listed in Table 6.         
 
 
Table 6 The mammalian RUNX genes synonyms and their locus (van Wijnen et 
al 2004) 
 
Gene Synonyms Chromosome locus 
RUNX1 CBFα2 AML1 PEBP2αB 21q22 
RUNX2 CBFα1 AML3 PEBP2αA 6p21 





1.2.1.2. Evolutionary conservation of RUNX 
RUNX genes are evolutionarily conserved in different organisms. Four genes have 
been reported in Drosophila melanogaster (Daga et al 1996, Kania et al 1990, 
Rennert et al 2003), one in sea urchin (Robertson et al 2002), one in Xenopus (Tracey 
et al 1998), four in zebra fish (Burns et al 2002, Crosier et al 2002, Kataoka et al 
2000), and one in Caenorhabditis elegans (Kagoshima et al 2005, Nam et al 2002, 
Nimmo et al 2005). RUNX homologs have also been described in basal metazoans, 
the most primitive organism described so far, with the findings of RUNX homologs in 
basal metazoans such as starlet sea anemone (Nematostella vectensis) (Ito 2008) and 
sponge (Oscarella carmela) (Kagoshima et al 2007). In mammals, there are three 
RUNX genes, namely RUNX1, RUNX2 and RUNX3. 
 
The mouse PEBP2αA1 (Runx2), mouse PEBP2αB1 (Runx1), and human PEBP2αC1 
(RUNX3) as well as Drosophila Runt proteins, PEBP2αA1 and PEBP2αC1 was found 
to be 93.8% identical in homology, whereas PEBP2αB1 and PEBP2αC1 was 93.0% 
identical in homology. Besides, a conserved five amino-acid sequence, VWRPY, is 
also present at the C-termini of all three Runt domain proteins, which is 100% 
conserved from Drosophila to human (Bae et al 1995). This VWRPY at the C-termini 
of the RUNX molecule plays a role in transcription regulation (Downing 1999, Ito 
1999). As shown in Figure 5, all RUNX proteins have a highly conserved Runt 
domain. 
 
Based on the genomic structure of the RUNX family of genes, RUNX3 is highly 
conserved throughout the evolution and thought to be the most ancient form of the 
three mammalian RUNX genes (Bangsow et al 2001). Since the expression of RUNX 
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homologs have been reported in the gut in various organisms, it is reasonable to 
suggest that RUNX genes, in particular RUNX3, are evolutionarily conserved growth 






Figure 5 A diagrammatic representation of Drosophila Runt, RUNX1, RUNX2 




1.2.2 Role of RUNX protein family 
The consensus sequence for RUNX binding is cited as either 5’-ACCPuCA-3’ or in 
reverse orientation, 5’-TG(T/C)GGT-3’. However, the sequence 5’-ACCACA-3’ 
appears more frequently in proven or bona fide RUNX target promoters than other 
sequences which are also in agreement with the consensus (Otto et al 2003). The 
RUNX protein family binds to the same DNA motif and regulates transcription of 
target genes through recruitment of transcriptional modulators. Although RUNX1, 
RUNX2 and RUNX3 share closely related structures and biochemical properties, they 




RUNX1 is involved in the development of normal hematopoiesis and the loss of 
function mutations is associated with 30% of all human leukemia. RUNX1 is the most 
frequent target of chromosomal translocations associated with human leukemia, with 
the TEL-AML t(12;21) fusion accounting for 20% of acute lymphoblastic leukemia 
(ALL) cases and the AML-ETO t(8;21) fusion accounting for 12% of acute myeloid 
leukemias (AML) (Speck and Gilliland 2002). Haploinsufficiency of RUNX1 due to 
heterozygous loss of function mutations is associated with familial platelet disorder, 
resulting in a predisposition to acute myeloid leukemia (Song et al 1999). This 
supported the hypothetical function of RUNX1 as tumor suppressor for AML. Besides, 
sporadic heterozygous mutations and point mutations of RUNX1 are also 
leukemogenic (Osato et al 1999). RUNX1 is also associated with several autoimmune 
diseases, including psoriasis, systemic lupus erythematosus and rheumatoid arthritis 
(Prokunina et al 2002, Tokuhiro et al 2003).  
 
1.2.2.2. RUNX2 
RUNX2 plays an important role in skeletal development, osteoblast maturation and 
osteogenesis (Komori et al 1997, Otto et al 1997). As one allele of the RUNX2 gene is 
inactivated, the haploinsufficiency of RUNX2 causes cleidocranial dysplasia, an 
autosomal dominant bone disease, characterized by defective development of the 
cranial bones and by the complete or partial absence of the collar bones (Lee et al 
1997, Mundlos et al 1997). Runx2 is part of a bone-specific regulatory network that 
controls normal cell cycle progression in osteoblasts and that is deregulated in 
osteosarcoma cells (Pereira et al 2009). Runx2 has also been described as an oncogene, 
whereby the overexpression of Runx2 pertubates T cell development in 
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lymphomagenesis by its cooperation with c-myc (Stewart et al 1997). However, the 
oncogenic property of Runx2 is something yet to be fully understood since both 
RUNX1 and RUNX3 are well-documented tumor suppressors.  
 
1.2.2.3. RUNX3 
As compared to RUNX1 and RUNX2, RUNX3 is involved in more diverse biological 
pathways. It is ubiquitously expressed in many cell types, including epithelial cells, 
mesenchymal cells and blood cells. In particular, RUNX3 is strongly expressed in the 
epithelial cells of the gastrointestinal tract and in the dorsal root ganglion neurons. It 
is also highly expressed in the haematopoietic system, with high levels in the spleen, 
thymus and blood. RUNX3 acts as a tumor suppressor in gastric cancer and other solid 
tumors. Since RUNX3 is involved in so many different cancer types, it may also be 
playing critical roles in different aspects of carcinogenesis. 
 
 
1.2.3 Gain or loss of RUNX genes in cancer 
Carcinogenesis is a multistep process characterized by genetic alterations that 
influence key cellular pathways involved in growth and development. The historical 
classification of cellular genes involved in carcinogenesis is a simple binary system 
consisting of two classes of genes – the oncogenes and the tumor suppressors. 
Oncogenes are defined as genes that promote cancer and whose alterations cause gain 
of function effects. In contrast, tumor suppressor genes are recessive genes whose 
functions are lost in cancer by either mutation or deletion (Shields and Harris 2000).  
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Al Knudson’s classical two-hit model of tumorigenesis suggested that tumor 
suppressor genes generally follow the 'two-hit hypothesis', which implies that both 
alleles that code for a particular gene must be affected before an effect is manifested 
(Knudson 1971). This is due to the fact that if only one allele for the gene is damaged, 
the second can still produce the correct protein. Both copies of the tumor suppressor 
gene are inactivated to promote tumor development, by chromosomal deletion and 
mutation (Nigro et al 1989).  
 
For the past few decades, Knudson’s model provided a useful framework for 
interpreting the genetics and biology of tumor suppressor gene activation. The 
discovery of DNA methylation (Hotchkiss 1948), as a powerful mechanism to 
influence gene control (Scarano 1971), was a significant milestone in cancer research. 
There are now several examples in which one copy of a tumor suppressor gene is 
wild-type but silenced by hypermethylation while the second copy is either mutated or 
lost, supporting the role of DNA hypermethylation as one of the primary, inactivating 
events contributing to tumorigenesis (Myohanen et al 1998). This challenged 
Knudson’s conventional two-hit hypothesis, and redefines his hypothesis to include 
epigenetic inactivation as one or both of the two hits required for tumor suppressor 
gene inactivation. 
 
The genes implicated in carcinogenesis are readily sorted into oncogenes and tumor 
suppressors. However, the RUNX family presents a challenge to this simple binary 
classification of cancer genes due to their paradoxical effects in cancer, in which they 
can function either as tumor suppressors or dominant oncogenes, in different lineages 
and cellular contexts. In all adult solid cancers analyzed to date, RUNX3 acts as a 
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tumor suppressor gene (Bae and Choi 2004) (down-regulation is associated with 
tumorigenesis). Prior to this thesis, our group showed that RUNX3 is frequently 
inactivated by dual mechanisms of protein mislocalization (Ito et al 2005) and 
promoter hypermethylation (Kim et al 2005). In a substantial fraction of gastric 
cancer cases in which RUNX3 was expressed, the protein was mislocalized in the 
cytoplasm as an inactive form. It is possible that disruption of machinery that controls 
nuclear transport of RUNX3 resulted in the sequestration or aberrant localization of 
RUNX3 in the cytoplasm. In fact, TGF-β was recently identified as one of the signals 
that control nuclear translocation of RUNX3 in a gastric cancer cell line (Ito et al 
2005). 
 
Inactivation of RUNX3 is detected in human cancers such as lung cancer (Sato et al 
2006, Yanagawa et al 2007), glioblastoma (Mueller et al 2007), breast cancer (Lau et 
al 2006), bladder cancer (Kim et al 2004) and gastric cancer (Kim et al 2004, Li et al 
2002) (Table 7). Although RUNX3 is inactivated in most cancers, it is reported to be 
activated in pancreatic cancer (Wada et al 2004) and as part of this thesis, in BCC 



















Table 7 RUNX3 in human cancers 
 
Type of cancer Status Mechanism References 
Lung cancer 
(NSCLC) Inactivation (25%) hypermethylation  
Sato et al 2006, 
Yanagawa et al 
2007 
Glioblastoma  Inactivation (56%) hypermethylation  Mueller et al 2007 




Lau et al 2006 
Bladder cancer Inactivation (52%) point mutation  hypermethylation  Kim et al 2004 




Kim et al 2004, Li 





Inactivation – cell 
line (75%) 
 
hypermethylation Wada et al 2004 
Basal cell   
carcinoma Activation (100%)  








1.2.4 RUNX3 and TGF-β tumor suppressor pathway 
TGF-β is a family of multifunctional cytokines that regulate the growth, 
differentiation, apoptosis, and matrix accumulation of wide varieties of cells (Blobe et 
al 2000). TGF-β is essential in many developmental and physiological processes. It 
acts as a potent growth inhibitor of most cell types, such as the epithelial cells, 
endothelial cells, hematopoietic cells and lymphocytes. Abnormalities in the TGF-β 
receptor affect downstream signal transduction pathways involved in the control of 
cell growth and differentiation, which often results in tumor progression, thus is 
regarded as a tumor suppressor pathway (Derynck et al 2001, Massague et al 2000). It 
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is interesting to note that some functions of the TGF-β superfamily cytokines are 
similar to those of RUNX proteins. For example, TGF-β acts on B lymphocytes and 
induces synthesis of IgA, and Runx1 exhibits a similar effect. BMPs induce bone 
formation, which is similar to the function of Runx2. TGF-β also regulates growth 
and apoptosis of gastric epithelial cells, which are also regulated by Runx3. The Runt 
domain transcription factors were found to be important targets of TGF-β superfamily 
signaling. Smad2 and Smad3 which act as signal transducers in the TGF-β signaling 
pathway were shown to interact with RUNX1, RUNX2 and RUNX3 in vitro (Hanai et 
al 1999). Physiologically, endogenous RUNX2 also interacts with endogenous Smad3 
in 10T1/2 and ROS17/2.8 cells (Alliston et al 2001). Receptor-regulated Smads (R-
Smads), signal mediators of the TGF-β superfamily cytokines, and Runx3 proteins 
have been shown to physically interact with each other (Ito and Miyazono 2003). R-
Smads, which are activated by TGF-β, interact with Runx3 proteins and cooperatively 
induce synthesis the downstream target genes (Figure 6). Hence, RUNX3 is a 
downstream target of the TGF-β signaling pathway, whereby RUNX3 forms 
complexes with Smads which in turn regulates target gene expression (Ito and 





















Figure 6 A schematic diagram of the transcription regulation by RUNX3 under 
the TGF-β tumor suppressor pathway (Ito and Miyazono 2003). Various cancers 
linked to mutations in the gene encoding TGF-β type I and type II receptors, Smad2/3, 
Smad4 (DPC4) and the transcriptional co-activator p300 were depicted in the diagram 






1.2.5 RUNX3 therapeutics 
In contrast to the classical tumor suppressors, in which both alleles are inactivated 
mainly by genetic alteration, RUNX3 is commonly inactivated by DNA methylation, a 
reversible epigenetic modification. Tumor suppressor genes that are silenced by DNA 
methylation could be good drug targets because these genes are not permanently 
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mutated and could be reactivated (Cameron et al 1999, Jones and Laird 1999). This 
re-expression of epigenetically inactivated genes could suppress tumor growth or 
increase sensitization to other anti-cancer therapies. Some DNA methylase inhibitors 
and histone deacetylase inhibitors that reverse epigenetic inactivation are now 
undergoing clinical trials in cancer patients (Brown and Strathdee 2002). RUNX3-
negative gastric cancer cell lines treated with Vorinostat (suberoylanilide hydroxamic 
acid), a new class of HDAC inhibitor, reactivated RUNX3, causing inhibition of tumor 
growth and apoptosis induction (Huang et al 2007). Together, the above results 
suggest that RUNX3 may be an effective therapeutic target for cancers, and also could 
be a good gene to monitor the overall effect or efficiency of DNA methylase 
inhibitors. Further research into the mechanisms that regulate the tumor suppressor 
activity of RUNX3 and the possible involvement of RUNX3 in a variety of cancers 
apart from gastric cancers may illuminate a new target in cancer treatment. 
 
The recognition that the delineation of the SHH signaling pathway may lead to certain 
cancers and the understanding of the pathway inhibition, have led to the development 
of potential therapeutic agents as targeted therapy in cancer. In contrast, the role that 
RUNX3 plays is relatively unknown and hence, acting upon RUNX3 has been done by 
indirect pathways and no direct therapeutic target has been developed or tested for 
RUNX3 related cancers. 
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CHAPTER 2   HYPOTHESIS 
 
2.1 Original hypothesis: Preliminary data leading to the focus of this thesis 
I undertook a comprehensive screening of cancer clinical samples of numerous kinds, 
as we hypothesized that the up-regulation or down-regulation of RUNX3 in human 
neoplasm was organ and cancer specific. This would suggest that, in different cancer 
types, RUNX3 would interact with different molecular pathways. Indeed, my 
preliminary results showed that RUNX3 is over expressed in BCC, a SHH signaling 
deregulated cancer (Salto-Tellez et al 2006) and, as such, contradicting the role of 
RUNX3 as tumor suppressors which is frequently inactivated in cancers (Bae and 
Choi 2004).  
 
2.2 Subsequent hypothesis: Core of the thesis 
Based on the confirmation of the preliminary hypothesis, we further hypothesized that: 
1. RUNX3 can work as a bona fide oncogene 
2. RUNX3 works as an oncogene in those cancer types which have a baseline 
derangement of the SHH pathway: BCC and DMB 
3. RUNX3 acts as an oncogene in the cancer models stated above by interacting 
with one of the key members of the SHH pathway. 
 
Since RUNX3 is a relatively new gene discovered in the 1990s (Ito 1999), its 
different roles in human are not fully explored. Hence, I explored the effect of 
RUNX3 overexpression in SHH-related neoplasms. This possible link may have 
practical implications: findings of possible connections between RUNX3 and SHH 
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signaling pathway may enable the development of useful molecular markers for 













3.1.1 Primers:  
 
Primers for sequencing of RUNX3 coding exons  
1. RUNX3 Exon 1  
Foward : 5’–GGGAAGCCGCGCCGTCTCC–3’  
Reverse : 5’–CGAGGCTCTGGCTCCCGCAGC–3’ 
 
2. RUNX3 Exon 2  
Foward : 5’–CCCTGGTCACCCTCTTCC–3’   
Reverse : 5’–CCTCTTTCAACCTCCTTCCC–3’  
 
3. RUNX3 Exon 3  
Foward : 5’–GAGCAGGGTATTGTGGAAGC–3’  
Reverse : 5’–CTGACCTAGCTGCTGTCCTTC –3’ 
  
4. RUNX3 Exon 4  
Foward : 5’–GCAGAGTGAGGCATTTCTGTC–3’  
Reverse : 5’–GATTGGACCACATCGAGGC–3’  
 
5. RUNX3 Exon 5_1  
Foward : 5’–AGCCCAAGGTCATTCTTCAG –3’   
Reverse : 5’–CGTGGGTGAGTTGCTGTG –3’  
 
6. RUNX3 Exon 5_2 
Foward : 5’–CATGCTGGCCTCTTGCAC–3’ 
Reverse : 5’–CAATGCTGCCTCTCTCTGG–3’ 
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Sequences of the RUNX3 siRNA:  
• siRNA-RUNX3-1 : 5’–GGCUUAGAAAAGGCGUAAG–3’(#146372, 
Ambion) 
• siRNA-RUNX3-2 : 5’–GGUUCAACGACCUUCGCUU–3’(#14497, Ambion)   
• siRNA-RUNX3-3 : 5’–GGCAAUGACGAGAACUACU–3’(#14403, Ambion) 
 
Primers for quantitative real time-PCR (pre-made by ABI)  
• hRUNX3 (ABI Assays on Demand Identifier, Hs00231709_m1)  
• hGAPDH (ABI Assays on Demand Identifier, Hs99999905_m1)  
 
Primers for detecting RUNX3 methylated DNA (No. 7; 115 bp): 
• Forward : 5′–TAATAGCGGTCGTTAGGGCGTCG–3′ 
• Reverse : 5′–GCTTCTACTTTCCCGCTTCTCGCG–3′  
 
Primers for detecting RUNX3 unmethylated DNA (No. 7; 115 bp): 
• Forward : 5′–ATAATAGTGGTTGTTAGGGTGTTG–3′ 
• Reverse : 5′–ACTTCTACTTTCCCACTTCTCACA–3′ 
 
Primers for cloning GLI1 promoter 
• Foward : 5'–GCCGGAGCTCAGCCGGGGTTCTAGGGAAAG–3'  
• Reverse:  3'–CAGACAGAGGTGAGAAGGGGGCTAGCCGGC–5' 
 
Sequences of RUNX3 pLKO-shRNA from OpenBiosystems  




Mature Sense : CCCAGCACTTTGTAGTCTCAT  
Mature Antisense : ATGAGACTACAAAGTGCTGGG 
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Mature Sense : CGAGAACTACTCCGCTGAGCT  
Mature Antisense : AGCTCAGCGGAGTAGTTCTCG 
 
3. pLKO.1 empty lentiviral vector (pLKO-ctrl) 
 
Primers for ChIP targeting GLI1 
1. GLI1 Site 1 
Foward : 5’–AAGGGGCTTCAGTCCCAGG–3’ 
Reverse : 3’–AAGCAAGGAGCAGCGGCT–5’ 
2. GLI1 Site 2 
Foward : 5’–CAGAGCCCCCAACCCAAC–3’ 
Reverse : 3’–CCCTTTGGATGGAACTTGCA–5’ 
3. GLI1 Site 3 
Foward : 5’–CGCTGCAAGTTCCATCCAA–3’ 
Reverse : 3’–CGCCTTTGGTTGGTGCTAA–5’ 
4. GLI1 Site 4 
Foward : 5’–ATCGAGGCTGCGCTGC–3’ 
Reverse : 3’–ATGCGCGGTCCAGGG–5’ 
5. GLI1 Site 1-2 
Foward : 5’–GACCTCGTGAACCACACCCT–3’ 
Reverse : 3’–CGGGACAGAGTTGCGGTTT–5’ 
6. GLI1 Site 2-3 
Foward : 5’–TGCCCCAAACCGCAACT–3’ 




3.1.2 Commercial kits  
 
• Purescript RNA Purification kit, R-5000W, Gentra  
• Puregene Tissue Core DNA Purification kit, 1042601, Gentra  
• ExoSAP-IT, 78200, USB 
• High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, 
4374966, Applied Biosystems 
• TaqMan Universal PCR Master Mix, 4304437, Applied Biosystems  
• TaqMan Fast Universal PCR Master Mix, 4352042, Applied Biosystems  
• 7900HT Gene Expression Micro Fluidic Card, Applied Biosystems 
• BigDye® Terminator v3.1 Sequencing Standard, 4336935, Applied 
Biosystems  
• QIAquick Gel Extraction Kit, 28706, Qiagen 
• QIAquick PCR Purification Kit, 28106, Qiagen 
• QIAprep Spin Miniprep Kit, 27106, Qiagen 
• QIAGEN Plasmid Maxi Kit, 12163, Qiagen  
• Dual-Luciferase Reporter Assay System, E1910, Promega  
• EZ DNA Methylation-Gold kit, D5005, Zymo Research 
• EnVision+ system (DAB), K4010; Dako  
• NE-PER Nuclear and Cytoplasmic Extraction Reagents, 78833, Pierce 
Biotechnology  
• BCA Protein Assay kit, 23225, Pierce Biotechnology 
• ECL Western Blotting Detection Reagents, RPN2106, Amersham 
Pharmacia Biotech   
• EZ ChIP Chromatin Immunoprecipitation kit, 17-371, Upstate cell 
signaling solutions  
• MISSION Lentiviral Packaging Mix, SHP001, Sigma-Aldrich 







3.1.3  Antibodies  
 
• Anti-RUNX3 (R3-5G4), mAb, mouse IgG, 0.5 μg/ml; a monoclonal antibody 
against RUNX3 established previously in our laboratory (Ito et al 2005)  
• Anti-RUNX3 (R3-6E9), mAb, mouse IgG, 0.7 mg/ml; a monoclonal antibody 
against RUNX3 established previously in our laboratory (Ito et al 2005) 
• Normal Mouse IgG, 12mg/ml, Sigma-Aldrich  
• Anti-β-catenin, mAb, mouse IgG, 250 μg/ml, #610154, BD Transduction 
Laboratories 
• Anti-GLI1, mAb, mouse IgG, clone L42B10, #2643, Cell Signaling 
Technology  
• Anti-Lamin A/C, mAb, mouse IgG, 612163, BD Transduction Laboratories 
 
 
3.1.4  General buffer preparation  
 
• Phosphate buffered saline (PBS) [137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM KH2PO4,  pH 7.4]  
• TE buffer [10 mM Tris-HCl, 1mM EDTA, pH 8.0]  
 
• Bacteria transformation  
o LB broth [1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 
0.5% (w/v) NaCl; pH 7.0]  
o LB agar [1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 
0.5% (w/v) NaCl, 2% (w/v) Bacto-agar]  
o SOC media [2% Bacto-tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose]  
 
• Agarose gel electrophoresis  
o 10X TBE [0.89 M Tris, 0.89 M Boric Acid, 0.02 M EDTA]  
o 6X Sample loading buffer [0.25% (w/v) Bromophenol blue, 0.25% 
(w/v) Xylene cyanol, 30% (v/v) Glycerol]  
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• SDS-PAGE and western blotting  
o Tris, pH 8.8 [1.5 M Tris base, 0.4% (w/v) SDS, pH adjusted to 8.8 
with concentrated HCl]  
o Tris, pH 6.8 [0.5 M Tris base, 0.4% (w/v) SDS, pH adjusted to 6.8 
with concentrated HCl]  
o 10X SDS-PAGE running buffer [0.25 M Tris base, 1.92 M Glycine, 
1% (w/v) SDS]  
o 1X Transfer buffer [0.025 M Tris base, 0.192 M Glycine, 10% 
methanol] 
o Blocking buffer [5% skim milk powder in 1X PBS]  
o Wash buffer [1X PBS, 0.1% Tween 20]  
o Stripping buffer [0.1% (w/v) SDS, 0.025 M Glycine, pH adjusted to 
2.0 with concentrated HCl] 
 
• SDS-PAGE gel  
o 8% Resolving gel:  
 30% Acrylamide  2.7 ml  
 1.5 M Tris (pH 8.8) 2.5 ml  
 10% APS   0.1 ml  
 10% SDS   0.1 ml  
 TEMED   0.006 ml  
 dH2O    4.6 ml  
 Total volume   10.0 ml  
 
o 5% Stacking gel:  
 30% Acrylamide  0.17 ml  
 1.0 M Tris (pH 6.8)  0.13 ml  
 10% APS   0.01 ml  
 10% SDS   0.01 ml  
 TEMED   0.001 ml  
 dH2O    0.68 ml  
 Total volume   1.0 ml  
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• Protein extraction  
o Lysis buffer [9 M Urea; 2% Triton-X; 5% final concentration of 2-
mercaptoethanol is added freshly before use]  
 
• Soft agar assay  





























3.2  Methods  
 
3.2.1  Collection and processing of human tissue samples  
 
3.2.1.1  Human cancer specimens  
A total of ninety eight formalin-fixed, paraffin-embedded tissue samples representing 
various skin neoplasms were obtained from the Pathology archives of the National 
University Hospital (NUH), Singapore (Table 8). All the hematoxylin and eosin 
stained sections were annotated by two dermato-pathologist (Prof Lee Yoke Sun & Dr 
Tan Kong Bing, NUH) to confirm the pathological diagnosis and define the 
representative tumor regions for subsequent sampling. The result, which we named 
DermPath-Array, allows for future screening of dermatological malignancies.   
 
Seventy five pairs of BCC and normal skin were obtained from National Skin Centre 
(NSC), Singapore. All the H&E stained sections were annotated by a skin specialist 
(Clinical A/Prof Tan Suat Hoon, NSC) to define the representative tumor regions for 
subsequent sampling. Four pairs of BCC and normal skin frozen skin were obtained 
from Singapore Tissue Network, with permission from NSC. 
 
Nineteen medulloblastoma cases were obtained from KK Women’s and Children’s 
Hospital, Singapore. Twenty three medulloblastoma cases were obtained from Sydney 
Medical School, The University of Sydney. All the H&E stained sections were 
annotated by two pathologists (A/Prof Manuel Salto-Tellez & Dr Victor Lee, NUH) 
to confirm the pathological diagnosis and define the representative tumor regions for 
subsequent sampling.  
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3.2.1.2  Tissue microarray construction  
All the H&E stained sections were annotated by various pathologists stated in section 
3.2.1.1, to confirm the pathological diagnosis and define the representative tumor 
regions for subsequent sampling. Tumor samples were arrayed as previously 
described in general by (Kononen et al 1998) (Figure 7) with modifications. The 
selected region in the donor block was punched with a 0.6 mm diameter tissue 
cylinder and the sample deposited directly into the recipient block with defined array 
coordinates, using a tissue-arraying instrument (Advanced Tissue Arrayer ATA100, 
Chemicon). After the construction of the array blocks was completed, multiple 
consecutive 4-μm sections were cut with a microtome until all of the tissue samples 
were represented on a single section. One section per block was placed on a 
microscopic slide and H&E stained for histological verification of the adequacy of the 
arrayed tumor and normal tissues. The consecutive sections were separately placed on 




















Figure 7 Tumor array construction (Kononen et al 1998). (a) Small tissue core 
biopsies are punched from selected regions of donor blocks using a thin-wall stainless 
steel tube sharpened like a cork borer. H&E stained sections overlayed on the surface 
of the donor blocks guide sampling from morphologically representative sites in 
tumors. (b) A solid stainless steel stylet transfers tissue cores into defined array 
coordinates in the recipient block. (c) An adhesive-coated tape sectioning system 
assists in cutting the tissue microarray block. This protocol was modified by cutting 
the sections from the block directly without the adhesive-coated tape as it causes high 
background during staining.   Each tissue element in the array is 0.6 mm in diameter 








Table 8 List of dermatological malignancies that was constructed into the 
DermPath-Array 
 
Cell of origin Name Number of cases 
Melanocytic Malignant melanoma 5 
  Naevi 5 
Squamous Actinic keratosis 3 
  Bowen's disease 5 
  Keratoacanthoma 5 
  Seborrheic keratosis 5 
  Squamous cell carcinoma 5 
Sebaceous Porocarcinoma 1 
  Poroma 5 
  Sebaceous adenoma 3 
  Sebaceous carcinoma 3 
  Sebaceous hyperplasia 5 
Fibroblastic Dermatofibroma 5 
  Dermatofibrosacroma protuberans 5 
Neural 
Malignant peripheral nerve sheath 
tumor 5 
  Neurofibroma 5 
  Schwannoma 5 
Vascular Angiosarcoma 5 
  Pyogenic granuloma 5 
Appendage Basal cell carcinoma 5 
  Trichoblastoma 3 
  Triepithelioma 5 






3.2.2  Microscopy Technique  
 
3.2.2.1  Immunohistochemistry (IHC)   
The tissue embedded in paraffin blocks is serially sectioned at 4 μm. Sections were 
placed on the surface of 70% ethanol to facilitate separation of serial sections into 
single section. Each serial section was transferred to water bath at approximately 37oC 
and left for few seconds for rehydration and fished out and displayed onto the poly-L-
lysine coated slides. Slides were left on heating block set to 37oC for approximately 1 
hr until sections were dried. Deparaffinization was carried out in xylene followed by 
rehydration of specimen in ethanol. Antigen retrieval was performed by boiling in 
citrate buffer at 120oC in a pressure cooker (Milestone, T/T Mega). After cooling the 
sections to room temperature, the sections were incubated with a protein block 
(X0909, Dako) for 10 min to block non-specific background staining, then suppresses 
endogenous peroxidases with a peroxidase block (S2003, Dako). Antibody was 
applied and incubated at room temperature (Table 9), visualized by EnVision G2 
Doublestain System (DAB), following manufacturer’s protocol (K5361, Dako). After 
immunostaining, the sections were counterstained with hematoxylin, dehydrated, and 
mounted with coverslips. The stained sections were analyzed under light microscopy 
by myself, and confirmed by a pathologist (A/Prof Manuel Salto-Tellez, NUH).  
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Table 9 List of conditions used for immunohistochemistry 
 
Antibody Dilution Incubation 
Anti-RUNX3 1 : 8000 Overnight 
Anti-β-catenin 1 : 1000 Overnight 
  
 
3.2.3  Cell lines and cell culture  
The following human cell lines were purchased from American Type Culture 
Collection (ATCC): normal skin cell line CRL-7761; BCC cell line CRl-7762; CMB 
cell lines D341med and HTB-185; and DMB cell line HTB-186. Monkey kidney cell 
line COS-7, human gastric carcinoma cell line SNU5 and human embryonic kidney 
cell line HEK293T, were obtained from fellow colleagues at the Cancer Science 
Institute. The skin cell lines are grown in Dulbecco’s Modified Eagle’s Medium with 
4 mM L-glutamine (Sigma-Aldrich, D1152) that is modified to contain 4.5 g/L 
glucose and 1.5 g/L sodium bicarbonate and supplemented with 10% fetal bovine 
serum (Biowest, S1810). The medulloblastoma cell lines are grown in Improved 
MEM with zinc option (Gibco, 10373) and supplemented with 10% fetal bovine 
serum. COS-7, SNU5 and HEK293T cell lines are grown in Dulbecco’s Modified 
Eagle’s Medium and supplemented with 10% fetal bovine serum. All the cells are 
maintained at 37oC with 5% CO2 in air atmosphere.     
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3.2.3.1  Treatment of cells by cyclopamine  
Cyclopamine, a major steroidal alkaloid of Veratrum californicum, is an extremely 
potent teratogen in several mammalian species when administered at a specific 
embryonic stage (Keeler 1978). Cyclopamine inhibits the SHH signaling pathway by 
direct binding to SMO (Chen et al 2002). Cyclopamine treatments were carried out 
using Improved MEM (Invitrogen, Paisley, UK) supplemented with 2% FBS, and the 
dosage used was 10 μM. Cells (2 × 106/flask) were seeded in triplicate flasks and 
allowed to grow to approximately 50% confluence prior to treatment. Cells were 
treated for 0, 24, 48 and 72 hr, and trypsinized for protein and total RNA extraction. 





Figure 8 The inhibition of SMO by cyclopamine in the SHH signaling pathway 
(Athar et al 2006). Cyclopamine inhibits the SHH signaling pathway by direct 
binding to SMO (Chen et al 2002). 
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3.2.4  Sequencing of RUNX3 coding  exons  
Genomic DNA of the following cell lines were extracted using the Puregene DNA 
purification kit (1042601, Gentra), following manufacturer’s protocol: CRL-7761 
(normal), CRL-7762 (BCC-derived), selected BCC tumors, D341med (CMB), HTB-
185 (CMB) and HTB-186 (DMB). The extracted DNA was amplified using the 
primers for sequencing of RUNX3 coding exons. 5 μl of PCR product was added to 2 
μl of ExoSAP-IT (78200, USB), and incubated at 37oC for 15 min and heating to 
80oC to inactivate the ExoSAP-IT. The DNA was then used for direct sequencing 
using BigDye Terminator v3.1 Sequencing Standard (4336935, Applied Biosystems). 
The sequencing product was purified with ethanol/EDTA, pelleted and sent for 
reading by a commercial company, FirstBase Singapore. The chromatograms were 
read and aligned by BioEdit. RUNX3 gene is 4270 bp in length and comprises of 6 
exons, as shown in Figure 7 (Appendix 3). The coding sequence spans from position 






Figure 9 Structure and sequence characteristics of RUNX3 (Bangsow et al 2001).  
This diagram shows the genomic organization of the human RUNX3 gene. Black 
boxes represent coding exons, whereas the other boxes represent UTRs. 
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 3.2.5  siRNA transient transfection 
Transient transfection was carried out using Lipofectamine 2000 reagent (Invitrogen) 
according to the manufacturer’s instruction. Three pre-made small interfering RNA 
(siRNA) for RUNX3: siRNA-RUNX3-1; siRNA-RUNX3-2; and siRNA-RUNX3-3, 
were purchased from Ambion and were tested for knockdown of RUNX3. siRNA-
RUNX3-2 was selected for experiments as the reduction of RUNX3 was most 
significant. 10 nM of oligomer was used to transfect each 100 mm dish and the cells 
were incubated at 37oC in a CO2 incubator for 24 hr for the gene knockdown assays.  
 
 
3.2.6  Quantitative real-time PCR analysis  
Total RNA was isolated by using Purescript RNA purification kit (Gentra, R-5000A) by 
following the manufacturer's instructions. For the reverse transcription reaction, high 
capacity cDNA archive kit (Applied Biosystems, 4322171) was used. The reverse 
transcription reaction was performed for 60 min at 37oC, followed by 60 min at 42oC by 
using oligo(dT) and random hexamers. PCR amplification was performed by using 
TaqMan Universal Master Mix. TaqMan assay reagents (probe and primer mixture) of 
GAPDH (ABI Assays on Demand Identifier, Hs99999905_m1) and RUNX3 (ABI Assays 
on Demand Identifier, Hs00231709_m1) were used to detect expression of the genes to 
check the quality of the cDNA before using these samples for the Taqman low density 
array (LDA). The LDA card was used to detect expression of 384 genes with reduced 
sample and regent consumption. This LDA card was specially designed to screen the gene 
profile of SHH signaling pathway, apoptosis, cell cycle, Wnt and TGF-β signaling 
pathway. Reactions were performed in duplicate containing 2 X Universal Master Mix, 2 
μl of template cDNA, 200 nM primers, and 100 nM probe in a final volume of 25 μl, and 
they were analyzed in a 96-well optical-reaction plate (Applied Biosystems). Probes 
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include a fluorescent reporter dye, 6-carboxyfluorescein (FAM), on the 5' end and labeled 
with a fluorescent quencher dye, 6-carboxytetramethyl-rhodamine (TAMRA), on the 3' 
end to allow direct detection of the PCR product. Reactions were amplified and quantified 
by using an ABI 9700 sequence detector and the manufacturer's corresponding software 
(Applied Biosystems). Relative quantity of the genes of interest’s mRNA was obtained by 
using the comparative Ct Method and was normalized by using pre-developed TaqMan 
assay reagent human GAPDH as an endogenous control (Applied Biosystems). 
 
 
3.2.7  Protein isolation  
Adherent cells with 90% confluency were washed twice with ice-cold PBS and 
harvested into a 1.5 ml eppendorf tube using a rubber policeman. Cells were 
centrifuged to collect cell pellet. Protein lysis buffer were added to the cell pellet 
followed by sonication twice for approximately 10 sec each on ice until cells were 
completely lysed. 1 μl of protein lysate was used for protein concentration 
measurement using the BCA method on the Beckman Coulter DU530 machine. The 
remaining protein lysate were added 10% lithium dodecyl sulphate (LDS) to a final 
concentration of 2%. Samples were kept on ice and were ready to load. Suspension 
cells were collected from culture flask into falcon tube and centrifuged to collect cell 
pellet, which was then rinsed twice with ice-cold PBS. Washed pellet was added 
protein lysis buffer and the same extraction procedure was carried out as above. 
Nuclear and cytoplasmic extracts were prepared using NE-PER Nuclear and 
Cytoplasmic Extraction reagents (Pierce).  
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3.2.8  SDS-PAGE and western blot analysis  
SDS-PAGE was run in 1 X SDS-PAGE running buffer at 100 V for approximately 
1.5 hr until the bromophenol blue dye migrated out of the gel. Proteins on SDS-PAGE 
gel were transferred to the PVDF membrane (pretreated with methanol) using the 
western blotting apparatus (BioRad). Western blot was carried out in 1 X transfer 
buffer at 70 V for 90 min at 4oC. Transferred membrane was blocked with 5% skim 
milk in PBS for 1 hr, rinsed once with washing buffer and incubated with the 
respective primary antibody at 4oC overnight. Membrane was washed three times for 
5 min each with washing buffer, followed by incubation with HRP-conjugated 
secondary antibody for 1 hr at RT. Membrane was washed again three time for 5 min 
each with washing buffer, and develop with the chemiluminescence detection 
solutions (Amersham Pharmacia Biotech.) using an X-ray film developer (Kodak). β-
actin expression was performed using a final concentration of 1:10000 dilution for β-
actin (Sigma) antibodies. Expression of RUNX3 was detected using 0.05 ug/ml of 
anti-RUNX3 (R3-5G4). Lamin A/C expression was performed using a final 
concentration of 1:1000 dilution for Lamin A/C (BD Transduction Laboratories) 
antibodies.   
 
 
3.2.9  Immunoprecipitation 
For detection of endogenous protein interactions, whole cell lysate was prepared from 
HTB-186 cells. Immunoprecipitation was performed using anti-GLI1 (Cell Signaling) 
or normal mouse IgG, together with Protein G Sepharose (Sigma), followed by a 
western blot analysis using anti-RUNX3 (5G4). 
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3.2.10  Methylation-specific PCR 
Methylation-specific PCR was performed as reported previously (Herman et al 1996), 
using the EZ DNA Methylation Gold kit (Zymo Research, D5005). Genomic DNA 
denatured by NaOH was treated with sodium bisulfite and purified. The DNA was 
subjected to PCR using the primer set used for detecting methylated DNA (No. 7; 115 
bp) and primer set used for detecting unmethylated DNA (No. 7; 115 bp). Methylated 
nucleotides were verified by sequencing the PCR products using the same primers. 
 
 
3.2.11  Promoter assay  
 
3.2.11.1  Cloning of GLI1 promoter  
The promoter region of human GLI1, which contains four of the RUNX3 DNA 
binding sites, spans a segment of 0.8 kb upstream from the GLI1 transcription start 
site (Appendix 4 and 5), and was amplified from the HTB-186 genomic DNA by PCR 
using the primers for cloning GLI promoter. PCR was carried out at 94oC for 1 min, 
and 35 cycles of 94oC for 30 sec, 68oC for 30 sec, 72oC for 2 min and a final cycle at 
72oC for 5 min using the Pfu Ultra polymerase (Stratagene). The amplified DNA 
segment was cloned into the pGL3-Basic vector (Promega) (Appendix 1) between the 
KpnI and SacI sites. Ligation product was transformed into the E. coli DH5α strain. 
Positive clones were picked and checked by sequencing. One clone with the right 





3.2.11.2  Dual-luciferase reporter assay  
Transfections into the COS-7 cell line were carried out using the Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer’s protocol. Upon transfection, 
COS-7 cells were incubated at 37oC for 48 hr before cells were harvested. All cells 
were subjected to the luciferase assay using a Dual-Luciferase Reporter Assay system 
(Promega) according to the manufacturer’s protocol. Active lysis was carried out for 
COS-7 cell pellets collected in 1.5 ml eppendorf tubes. Cells were pelleted after cell 
lysis and 20 μl of cell supernatant was used for the luciferase assay. Luciferase assay 
was carried out as depicted in Figure 10 using the Sirius luminometer (Berthold 
Detection System) in triplicates. All firefly luciferase activity was normalized by the 


































Figure 10 Format of the dual-luciferase reporter assay. The firefly reporter assay 
is initiated by mixing an aliquot of lysate with the Luciferase Assay Reagent II. 
Upon completion of the firefly luciferase assay, the firefly luminescence is 
quenched and Renilla luminescence is simultaneously activated by adding Stop & 






3.2.12  Stable knockdown of RUNX3 
 
3.2.12.1  Generation of lentiviruses 
1 x 106 cells/100 mm dish HEK293T cells were plated in complete DMEM media, 
supplemented with growth media, 24 hr prior to transfection. pLKO.1 lentiviral 
plasmids (Appendix 6) for RUNX3 shRNA and a negative control were purchased 
from OpenBiosystems. Lentiviruses were generated by co-transfecting HEK293T 
cells with 2.6 μg of shRNA-encoding plasmid (pLKO-ctrl, pLKO-68 and pLKO-72) 
(Figure 11b) and 26 μl of MISSION Lentiviral Packaging Mix (containing 
pMISSIONgagpol and pMISSIONvsvg) using Lipofectamine 2000 (Invitrogen) 
(Figure 11a). Growth media was exchanged the following day and lentivirus-
containing supernatant was harvested 24 hr later. The supernatent with viral particles 




















Figure 11 Lentiviral particles are packaged in producer cell lines such as 
HEK293T cells. (a) Upon co-transfection of the plasmids, all required sequences are 
available to produce and package a viral particle containing the transgene of interest. 
Only the region between the viral LTRs of the transfer vector is packaged within the 
viral capsid. (From the Sigma MISSION Lentiviral Packaging Mix manual) (b) 






3.2.12.2  Lentiviral infection  
The target cell line HTB-186 was transduced with lentiviral inducible RNAi (Figure 
12). Cells were allowed to grow for 24 hr, followed by the addition of antibiotic for 
selection of transfected cells. 1 μg/ml puromycin was used based on the antibiotic 
selection of the vector used. Previously, the cells were treated with various 
concentrations of antibiotic to ensure the proper dosage for antibiotic kill-curve, the 
dose response curve. Cell growth was monitored in the presence of antibiotic. Cells 
were harvested and divided into four portions: for extraction, sub-culturing, MTS 
assay, soft agar assay and subcutaneous injection into mice. The efficiency of the 
knockdowns was determined by harvesting the cells for western blotting and real-time 





Figure 12 Schematic protocol for subcutaneous injection of RUNX3 knockdown 
cell lines into NOD/SCID mice with lentiviral-mediated gene transfer. Lentiviral 




3.2.13  MTS assay 
The MTS assay was performed according to the manufacturer's protocols (Promega, 
Madison, WI, USA). Cells were plated at a seeding density of 1 × 104 cells per ml in 
triplicate. CellTiter 96® Aqueous One Solution Reagent (Promega, Madison, WI) was 
added to each well according to the manufacturer’s instructions.  Cell numbers were 
estimated after 0, 24, 48, 72 and 96 hr by adding MTS to the wells 1 hr before 




3.2.14  Measurement of cell viability  
The treated cells were subjected to a cell count assay to determine cell viability before 
it was used for soft agar assay or injected into NOD/SCID mice as xenografts. Viable 
cell counts were obtained using a hemocytometer to count trypsinized, trypan blue 
negative live cells and dead cells that were stained with trypan blue. 
 
 
3.2.15  Invasion assay and anchorage-independent growth assay in soft agar 
A 1% solution of sterile DNA-grade agarose was mixed with 2 X medium, and the 
0.5% base solution was added to 60 mm dishes and was solidified. The transformed 
cells (2500 cells per ml in 2 X media) were mixed with a 0.6% agarose solution, and 
7500 cells were added to the base agarose. The plates were incubated at 37oC for 5 
weeks and fed 1 - 2 times per week with cell culture media. Cells were fixed with 
methanol and stained with 0.005% crystal violet. 
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3.2.16  Xenografts in NOD/SCID Mice  
Each of HTB-186 + pLKO-ctrl, HTB-186 + pLKO-68 and HTB-186 + pLKO-72 
infected cell lines (0.5 x 106 cells respectively in PBS and Matrigel Matrix, BD 
Biosciences 356234) were injected subcutaneously into the flanks of 8 approximately 
2-mth old NOG mice using a 27 ½ gauge needle (Figure 13). When the tumors grow 
to approximately 1 cm of size, they were excised out and mass (g) was measured. 







3.2.17  Chromatin immunoprecipitation (ChIP) assays 
ChIP was performed using an EZ ChIP kit (Upstate Biotechnology). HTB-186 and 
CRL-7762 cells were crosslinked in 1% formaldehyde for 10 min. The cross-linking 
reaction was stopped by the addition of 0.125 M glycine for 5 min. Cells were washed 
Figure 13 Nude mice assay with RUNX3 knockdown cell lines. Experiment to observe if 
knock-down of RUNX3 in tumorigenic HTB-186 cells enhances tumorigenicity in 
NOD/SCID mice. 
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with ice-cold PBS containing protease inhibitors and lysed in SDS lysis buffer 
containing protease inhibitors. Samples were sonicated on ice to an average size of 
200–1,000 bp and centrifuged for 10 min at 14,000 rpm at 4oC to remove insoluble 
material. Chromatin was precleared with salmon sperm DNA/protein G agarose for 1 
hr at 4oC, and 1% of this solution was saved (input chromatin) and processed with the 
eluted immunoprecipitates beginning with the cross-link reversal step. Samples were 
incubated overnight at 4oC with anti-RUNX3 antibody (Clone 6E9) or isotype-
matched control IgG (negative control) with rotation. Immune complexes were 
collected by incubating samples with salmon sperm DNA/protein G agarose for 1 hr 
at 4°C with rotation. The beads were pelleted by brief centrifugation and washed as 
per the manufacturer’s instructions. The immunocomplexes were eluted from the 
agarose beads by elution buffer (1% SDS and 0.1 M NaHCO3). Input and 
immunoprecipitated chromatin were incubated with 200 mM NaCl at 65oC for 4 hr to 
reverse DNA–protein cross-links. The immunoprecipitated DNA was purified as per 
the manufacturer’s instructions (Upstate Biotechnology) and analyzed by PCR using 
primers for ChIP targeting GLI1. 
 
3.2.18  Statistical analysis  
Statistical evaluation was performed using the student’s unpaired, two-tailed t-test to 
determine statistical significance, where indicated. Data in this thesis are presented as 
mean ± SD and analysed with Graphpad Prism Software. A value of p < 0.05 was 
considered statistically significant.  
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CHAPTER 4   RESULTS  
 
4.1 RUNX3-SHH at a protein level: Is RUNX3 protein overexpression related to 
SHH signaling? 
 
4.1.1 Expression of RUNX3 in different skin malignancies 
Before the first manuscript derived from the work of this Ph.D. (Salto-Tellez M, Peh 
BK et al, Oncogene 2006) the expression of RUNX3 in skin malignancies was 
unreported. Thus, an across-the-board screening of RUNX3 protein expression in 
dermatological malignancies was performed. A tissue microarray with ninety eight 
cases, representing neoplasms and pre-neoplastic lesions of all skin lineages (which 
we named DermPath-Array) was constructed, and the expression of RUNX3 protein 
was analyzed by immunohistochemistry (Table 10). RUNX3 is a cellular transcription 
factor that is active in the nucleus (Katinka et al 1980, Tanaka et al 1982) and is 
frequently inactivated by dual mechanisms of protein mislocalization in the cytoplasm 
(inactive form, (Ito et al 2005) and promoter hypermethylation (Kim et al 2005). Thus, 
nuclear expression characterizes a positive IHC analysis, while lack of expression or 
cytoplasmic only expression represents a “negative” result. 
 
In the normal skin, RUNX3 is expressed in approximately 70% of the cells, with 
moderate intensity, and this represents the “baseline” expression for comparison 
(Figure 14a and b). In general, skin malignancies of different histogenesis showed 
varied expression patterns (Figure 14). For instance, there is no expression of RUNX3 
in dermatofibroma (Figure 14c, a neoplasm with a fibroblastic histogenesis) and 
strong cytoplasmic but no nuclear expression in schwannoma (Figure 14d, a neoplasm 
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with a neural nature). The benign naevus, a melanocytic lesion, has a degree and 
intensity of nuclear expression (Figure 14e), which is similar to normal skin. In 
general, RUNX3 protein expression was maintained or down-regulated in most skin 
malignancies, mirroring the known pattern in most solid neoplasms (see introduction).  
 
15% (15 of 98) of the cases showed cytoplasmic expression, 18% (18 of 98) of the 
cases showed nuclear expression and 66% (65 of 98) of the cases did not express 
RUNX3. There are no cases that expressed RUNX3 in both nuclear and cytoplasm 
and it is likely to be due to the fact that RUNX3 is functionally inactivated by 
subcellular mislocalization in the cytoplasm (Ito et al 2005).  
 
However, there was universal up-regulation in 2 types of neoplasms with skin 
appendage origin, namely BCC and trichoepithelioma. Skin appendages are 
derivatives of epidermal epithelia that elaborate to form specialized structures and 
functions around the hair shaft and the hair follicle. Epithelia can protrude to form 
hairs, nails or invaginate to form glands. Therefore, skin appendages include the hair, 
nails, sebaceous glands, sweat glands, and the mammary glands (indeed, from a pure 
histogenetic viewpoint, breast glands and ducts can be considered modified sweat 
gland structures). As shown in Figure 14f, trichoepithelioma has strong RUNX3 
protein up-regulation in the nuclei. In this array, BCCs were showing a similar pattern 
of expression. In view of the specific relevance of the latter, a TMA composed of 






Table 10 List of dermatological malignancies screened for RUNX3 protein 
expression 
 




of cases Absent Cytoplasmic Nuclear 
Melanocytic Malignant melanoma 5 √   
  Naevi 5   √ 
Squamous Actinic keratosis 3 √   
  Bowen's disease 5 √   
  Keratoacanthoma 5 √   
  Seborrheic keratosis 5 √   
  Squamous cell carcinoma 5 
√   
Sebaceous Porocarcinoma 1 √   
  Poroma 5 √   
  Sebaceous adenoma 3 √   
  Sebaceous carcinoma 3 √   
  Sebaceous hyperplasia 5 √   
Fibroblastic Dermatofibroma 5 √   
  Dermatofibrosacroma protuberans 5 
√ 
  
Neural Malignant peripheral nerve sheath tumor 5 
 
√  
  Neurofibromatosis 5  √  
  Schwannoma 5  √  
Vascular Angiosarcoma 5 √   
  Pyogenic granuloma 5 √   
Appendage Basal cell carcinoma 5   √ 
  Trichoblastoma 3   √ 
  Triepithelioma 5   √ 



































Figure 14 Immunohistochemical detection of RUNX3 expression in different skin 
malignancies tissue samples with anti-RUNX3 monoclonal antibody R3-6E9. A 
low-power view of a TMA punch and its high-power view emphasizing cellular 
expression. a) H&E stain on normal epidermis; (b) corresponding RUNX3 expression 
in normal epidermis; (c) Dermatofibroma did not have any nuclear expression; (d) 
Schwannoma showed strong cytoplasmic but no nuclear expression; (e) Naevus had 
some nuclear expressions; (f) Trichoepithelioma had RUNX3 protein up-regulation in 
the nuclei. 
Naevus: No protein up or down  
regulation; no cytoplasmic mislocalization 
Trichoepithelioma: 
RUNX3 protein upregulation  
d
e f
Schwannoma: strong cytoplasmic but no 
nuclear expression 





4.1.2 Expression of RUNX3 in normal skin and BCC 
To confirm the observations from the DermPath Array, the expression profile of 
RUNX3 was studied. A separate TMA was constructed with seventy five BCC 
clinical samples and their normal epidermal counterparts. Immunohistochemical 
staining showed that RUNX3 protein is expressed in normal skin (Figure 15a) in a 
way similar to what was described in section 4.1.1, namely with distinct nuclear, 
mild-to-moderate positivity in approximately 75% of epidermal cells (Figure 15b). 
The expression is present in all the epidermal layers, although the number of RUNX3-
expressing cells is particularly prominent in the basal cell layer, but patchy in the 
prickle cell, granular cell and keratin layers. The expression is also prominent in the 
hair shaft, being more prominent in the outer root sheath of the pilosebaceous unit and 
the associated eccrine sweat glands (data not shown). The analysis of BCC samples 
showed that there is a strong, uniform nuclear expression of the RUNX3 in all seventy 
five cases (Figure 15c and d). The expression was present in virtually 100% of the 
BCC neoplastic cells, irrespective of the histological subtype. Furthermore, 
expression of RUNX3 within the well-demarcated ‘islets’ of neoplastic cells is 
distinctly higher than that of the adjacent normal epidermal tissue. Taken together, 























Figure 15 Immunohistochemical detection of RUNX3 expression on skin tissue 
samples with anti-RUNX3 monoclonal antibody R3-6E9. (a) H&E stain on normal 
epidermis; (b) corresponding RUNX3 expression in normal epidermis; (c) low-power 
view of a TMA punch including normal epidermis and BCC in the dermis; (d) high-
power view showing a rim on normal epidermis (top) and the nodules of infiltrating 






4.1.3 Expression of RUNX3 in medulloblastoma 
RUNX3 is overexpressed in BCC, a SHH-deregulated cancer and thus, RUNX3 might 
play a role in other SHH-related diseases. Although the SHH signaling pathway is 
turned off in most adult tissues, it is known to be activated in medulloblastoma (Oldak 
et al 2001). Microscopically, the medulloblastoma tumor cells are small with little 
cytoplasm (Figure 16a and c). They are arranged in sheets and may show signs of 
neuronal or glial differentiation. Histological subtypes of medulloblastoma have been 
described and include the desmoplastic variant and the conventional large cell variant. 
The desmoplastic variant is composed of islands of smaller, more typical 
medulloblastoma cells with abundant collagenous matrix (Figure 16a). In the 
conventional large cell variety, the cells are larger and more pleomorphic (Figure 16c). 
Microscopically, the tumor is invasive at its edges, although penetration into the 
surrounding cerebellum is somewhat limited. While the conventional 
medulloblastoma showed no RUNX3 expression (Figure 16b), the desmoplastic 
subtype (associated with a SHH-related oncogenesis, as discussed in the introduction) 


































Figure 16 Immunohistochemistry for RUNX3 on conventional and desmoplastic 
medulloblastoma samples. (a) Photograph of a human DMB, H&E stain. (b) DMB 
had strong, nuclear RUNX3 expression. (c) Photograph of a human CMB, 
demonstrated as small, tightly packed cells with little cytoplasm and an abundant 









4.1.4 Expression of β-catenin in normal skin and BCC 
The Wnt pathway is involved in hair follicle morphogenesis and its ligands are known 
targets of SHH signaling (Andl et al 2002, Reddy et al 2001). The deregulation of 
Wnt pathway is linked to the progression of human melanomas (Rubinfeld et al 1997, 
Weeraratna 2005). To verify the involvement of Wnt pathway in BCC, the BCC TMA 
samples was analyzed for β-catenin expression and subcellular localization. β-catenin 
is a 92 kDa protein that binds to the cytoplasmic tail of E-cadherin. The cadherins, 
transmembrane adhesion molecules, are found with catenins at adherens junctions 
(zonula adherens). Deletions in the cytoplasmic domain of E-cadherin which 
eliminate catenin binding also result in a loss of cell adhesion, indicating that this 
binding is essential for E-cadherin function. There was nuclear accumulation of β-
catenin in 31 of 75 (41%) BCC tumor samples. Whereas the expression of β-catenin 
is uniformly restricted to the cell membrane in normal epidermis (Figure 17a and b), 
its expression varied considerably between BCC samples. Expression ranged from 
being undetectable (Figure 17c) to predominant expression in the nucleus (Figure 
17d), cytoplasm (Figure 17e) or cytoplasm and membrane (Figure 17f). In certain 
cases, combined expression in the cytoplasm and nucleus, or membrane was observed 
(Figure 17d and f, respectively). Together, these observations suggest that activation 
of Wnt signaling is evident in a subset of BCC, as the subcellular localization of β-












Figure 17 Immunohistochemistry for β-catenin on normal and BCC samples. 
Immunohistochemistry staining by anti-β-catenin mouse monoclonal antibody was 
performed. (a) H&E stain on normal epidermis; (b) corresponding β-catenin stain 
with characteristic membranous positivity; Expression of β-catenin in BCC samples 
ranges from (c) no expression; (d) nuclear and membranous; (e) cytoplasmic only; 




4.1.5 Western blot analysis of RUNX3 protein expression in normal and BCC cell 
lines  
To confirm the observation of BCC’s RUNX3 protein overexpression, a western blot 
analysis on normal skin (CRL-7761) and BCC-derived (CRL-7762) cell lines, using a 
RUNX3-specific monoclonal antibody R3-5G4 (Ito et al 2005), was performed. 
Figure 18 shows that the RUNX3 proteins expressed in CRL-7762 cells are of the 
same length as that of ectopically expressed, full length RUNX3 in transfected COS-7 
cells, suggesting that functional RUNX3 is expressed in BCC cells. Importantly, 
RUNX3 expression is markedly stronger in CRL-7762 compared to the normal CRL-
7761, confirming the observation of RUNX3 protein overexpression in BCC TMA 
samples. Two RUNX3-related bands were detected in CRL-7762 and SNU5 cell 
lysates, which may represent different RUNX3 isoforms, although the doublet could 
also be caused by phosphorylated or proteolytically degraded forms of RUNX3 







Figure 18 Western blot analysis of RUNX3 expression in normal skin and BCC 
cell lines. Whole-cell extracts from COS-7 cells expressing exogenous RUNX3; normal 
skin cell line CRL-7761; BCC-derived cell line CRL-7762; and gastric cancer line 
SNU5, which overexpressed endogenous RUNX3. Western blot was performed using
RUNX3-specific monoclonal antibody R3-5G4, as described by (Ito et al 2005). 
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4.1.6 Western blot analysis of RUNX3 protein expression in medulloblastoma cell 
lines 
To confirm the observation of RUNX3 overexpression in desmoplastic 
medulloblastoma, a western blot analysis was performed. Firstly, the nuclear and 
cytoplasmic fraction was separated from the whole-cell lysates of SNU5 cells, CMB 
D341med cells and HTB-185 cells, and DMB HTB-186 cells, using Pierce NE-PER 
Nuclear and Cytoplasmic Extraction Kit. Then, a western blot analysis on these 
nuclear and cytoplasmic extracts, using a RUNX3-specific monoclonal antibody R3-
5G4 (Ito et al 2005) was performed. Figure 19 shows that the RUNX3 proteins were 
expressed in the DMB cells HTB-186, but not in the CMB D341med and HTB-185. 
As the expression of RUNX3 is localized in the nuclei of HTB-186, this suggests that 
functional RUNX3 is expressed in HTB-186. Importantly, this confirms the 
observation of RUNX3 overexpression in a histological subtype of medulloblastoma, 


































4.2 RUNX3-SHH: gene expression, methylation and sequencing evidence   
From the RUNX3 protein results, both BCC CRL-7762 and DMB HTB-186 cell lines 
exhibit up-regulation of RUNX3, which is localised in the nuclei, hence as active 
form. Moreover, in BCC and medulloblastoma, the SHH pathway which has a 
minimal role in most adult tissues, is known to be activated (Oldak et al 2001). CRL-
7762 is very slow growing as compared to HTB-186. Due to the different growth rate 
of these two cell lines, some experiments were done selectively using one of these 
two cell lines, whichever allowed a better optimization of the assays in question. We 
presume that, as both cell lines are RUNX3 overexpressing and SHH-related, the 
results in either cell line would provide important insights on the RUNX3-SHH 
interaction. 
Figure 19 Western blot analysis of RUNX3 expression in nuclear and cytoplasmic 
extracts of medulloblastoma cell lines. Whole-cell lysate from SNU5 cells expressing 
endogeneous RUNX3; conventional medulloblastoma cell line D341med and HTB-
185; desmoplastic medulloblastoma cell line HTB-186; were subjected to nuclear and 
cytoplasmic separation using Pierce NE-PER Nuclear and Cytoplasmic Extraction Kit. 
Western blot was performed using RUNX3-specific monoclonal antibody R3-5G4, as 
described by (Ito et al 2005). Lamin A/C and β-actin antibodies were used as loading 
controls, and Lamin A/C binds specifically to nuclear proteins. 
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4.2.1 Results of gene expression analysis in BCC clinical samples 
BCC clinical frozen samples were obtained from a collaborator at the National Skin 
Centre. A few cryosections were taken from these frozen samples and analyzed 
histologically to confirm the presence of BCC in the samples. Total RNA was 
extracted, reverse-transcribed and the cDNAs were loaded into Low Density Array 
(LDA) Cards for Real-Time PCR analysis. These results were analyzed with GAPDH 
as the endogenous control, and compared against a normal clinical skin frozen sample 
as the gene expression baseline. The relative expression levels were calculated on a 
log10 scale and presented in Figure 20. In concordance with the protein analysis of 
RUNX3 in BCC, RUNX3 mRNA was higher in BCC clinical samples as well. 
Interestingly, the direct targets of SHH signaling pathway, GLI1 (Yoon et al 2002), 
HHIP1 (Vokes et al 2007) and PTCH (Yoon et al 2002) were up-regulated in BCC 
(Figure 20a). The SHH gene encodes the SHH ligand, that will bind to the receptor 
PTCH, to relieve the repression of SMO, leading to activation of downstream target 
genes in the pathway (Athar et al 2006). Hence, the higher level of SHH mRNA 
denotes the presence of more activating ligands of SHH signaling. In particular, GLI1 
acts as the positive feedback and has been used as an indicator of activation of SHH 
signaling pathway. Therefore, the up-regulation of GLI1 in BCC implies that the SHH 
signaling pathway is up-regulated in BCC. Besides, another transcriptional activator 
GLI2 was also up-regulated. The increased expression of GAS1 blocks entry to S 
phase and prevents cycling of normal and transformed cells, which may account for 
the slow growth of BCC. Figure 20b is a simplified SHH signaling pathway (modified 
from Athar et al 2006), with arrows indicating up-regulation, to better relate the gene 





Figure 20 Gene expression analysis of the SHH signaling pathway in two BCC 
clinical frozen samples. (a) Total RNA was extracted, reverse-transcribed and loaded 
into the LDA cards for RT-PCR. These results were analyzed with GAPDH as the 
endogenous control, and compared against a normal clinical frozen sample as control. 
The relative expression levels were shown on a log10 scale. The results indicate that 
SHH signaling pathway is activated in BCC. (b) Simplified SHH signaling pathway in 
BCC (modified from Athar et al 2006). The expression levels of the various genes 
were derived from the gene expression analysis of BCC clinical samples. The red 




4.2.2 Results of mRNA gene expression in cell lines  
To investigate the relationship of RUNX3 and the SHH signaling pathway, a transient 
knockdown of RUNX3 was performed (Figure 21). After the transient siRNA 
transfection of the RUNX3 endogenously expressed BCC cell lines (CRL-7762) and 
DMB (HTB-186), the total RNA was extracted, reverse-transcribed and amplified the 
cDNA with real-time PCR (LDA Cards). Negative control siRNAs are siRNAs with 
sequences that do not target any gene product and are essential for determining 
transfection efficiency and to control for the effects of siRNA delivery. Hence, siRNA 
knockdown of firefly luciferase is selected as negative control. The gene expression 
results of the SHH signaling pathway are presented in Figure 21. With the knockdown 
of RUNX3, the direct targets of the SHH signaling pathway, GLI1 and HHIP1 were 
down-regulated. GLI1 acts as the positive feedback and has been used as an indicator 
of activation of SHH signaling pathway. Therefore, the knockdown of RUNX3 led to 
the down-regulation of GLI1 which implied that the SHH signaling pathway was 




































Figure 21 Transient knockdown of RUNX3. (a) Gene expression analysis of the 
SHH signaling pathway in CRl-7762 and HTB-186 cells with siRNA knockdown of 
RUNX3. These results were analyzed with GAPDH as the endogenous control, and 
compared against cells with siRNA knockdown of firefly luciferase as control. The 
relative expression levels were shown on a log10 scale. The results indicate that SHH 
signaling pathway is down-regulated in BCC and DMB cell lines. (b) Simplified SHH 
signaling pathway in BCC (modified from Athar et al 2006). The expression levels of 
the various genes were derived from the gene expression analysis of transient 
knockdown of RUNX3. The red arrows indicate up-regulation and green arrows 





4.2.3 RUNX3 Mutation Screening  
 
4.2.3.1 Sequencing 
To provide direct evidence that the RUNX3 proteins overexpressed in BCC and DMB 
are full length and intact, the RUNX3 gene was analyzed for mutations. The entire 
RUNX3 coding region of CRL-7761 (normal), CRL-7762 (BCC-derived), selected 
BCC tumors, D341med (CMB), HTB-185 (CMB) and HTB-186 (DMB), was 
sequenced (Figure 22). The analyses showed no evidence of mutation in the RUNX3 
coding region (Figure 22a and b). The only mutation detected was a nucleotide 
change from C→T at position 28 bp of RUNX3 intron 4 in normal skin tissue (Figure 
22c), which is not transcribed and does not affect the expression of RUNX3. 
Therefore, the data indicate that the overexpressed RUNX3 in BCC and DMB is 
without structural alteration or mutation, and fully functional. 
 
 
4.2.3.2 RUNX3 methylation 
To investigate whether RUNX3 is silenced by promoter hypermethylation, DNA from 
cells of HCT116, SNU1, CRL-7761, CRL-7762, HTB-185, HTB-186, D341med and 
SNU5 was extracted. After bisulfite treatment, the samples were amplified and 
analyzed on agarose. From the results of Homma et al 2006, if region 5-8 were 
unmethylated or partially methylated, RUNX3 mRNA was detected. Therefore by 
screening region 7, which is the transcriptional start site, any inactivation of RUNX3 
by methylation can be detected. Based on the results of Homma et al 2006 on region 7, 
which is the transcriptional start site, the skin and medulloblastoma cell lines were 







Figure 22 Chromatogram of RUNX3 sequencing. (a and b) Chromatogram of 
RUNX3 exon 2 in normal skin and BCC cell lines. No mutation was detected.  (c) 
Chromatogram of RUNX3 intron 4 in normal skin tissue. There was a nucleotide 
change from C→T at position 28 bp of RUNX3 intron 4. 
 
RUNX3 Exon 2, BCC Cell line CRL-7762 
RUNX3 Exon 2, Normal Skin Cell line CRL-7761 
(a) 
(b) 
Normal skin tissue 
Intron 4 at  position 28bp, 
nucleotide change from 
C→T 





















Figure 23 RUNX3 methylation. (a) RUNX3 CpG island and analyzed regions (No. 
1–10) (From (Homma et al 2006). CpG sites are shown as vertical bars. 
Transcriptional start site (TS) is located within region No. 7. (b) Summary of 
methylation and expression status of RUNX3 in gastric cancer cell lines. From the 
results, if region 5-8 is is unmethylated or partially methylated, RUNX3 mRNA is 
detected. Therefore by screening region 7, which is the transcriptional start site, the 
inactivation of RUNX3 by methylation can detected. (c) Based on our results on 
region 7, the skin and medulloblastoma cell lines were unmethylated. U is for 
































4.3 In SHH-related neoplasms, Runx3 acts as an oncogene 
 
4.3.1 Effects of stable knockdown of RUNX3  
As shown in Figure 19, DMB HTB-186 cells expressed high endogenous level of 
RUNX3. To investigate if RUNX3 shRNA can inhibit tumorigenesis in vitro, HTB-
186 cells was infected with lentiviruses expressing two types of RUNX3 shRNA, 
namely pLKO-68 and pLKO-72 and a negative control shRNA pLKO-ctrl, followed 
by monitoring the level of endogenous RUNX3 weekly. There was a significant 
decrease in the endogenous level RUNX3 in the HTB-186 cells infected with pLKO-
68 and pLKO-72, as compared with negative control shRNA, pLKO-ctrl (Figure 24a). 
There was 100% reduction of endogenous RUNX3 in the first week after puromycin 
selection. However, the cells gradually restored endogenous RUNX3 from the second 
week onwards.  
 
To determine whether these shRNAs induce the interferon response, the expression 
level of the various targeted genes with one interferon response genes, OAS1, was 
quantified one week after puromycin (Figure 24b). These results were analyzed with 
GAPDH as the endogenous control, and compared against a control, HTB-186 
infected with pLKO-ctrl. The expression levels of interferon response gene OAS1, 
were lower in the cells infected with pLKO-68 and pLKO-72. These results indicate 
that RUNX3 shRNAs (pLKO-68 and pLKO-72) do not induce a non-specific 
interferon response as compared to the negative control. The cell numbers were 
estimated by MTS assay weekly. A RUNX3 silencing resulted in significant reduction 










































































Figure 24 Effects of RUNX3 shRNA knockdown in HTB-186 after puromycin 
selection. (a) Immunoblotting of RUNX3 shRNA knockdown in HTB-186 after 
puromycin selection. The cells were harvested every week, to monitor the knockdown 
effect on RUNX3 in HTB-186. 20 μg of whole cell lysate was loaded per lane. β-actin 
was used to normalize the amount of protein loaded. (b) Gene expression in HTB-186 
infected with pLKO-68 and pLKO-72. These results were analyzed with GAPDH as 
the endogenous control, and compared against a control, HTB-186 infected with 
pLKO-ctrl. The expression level of interferon response gene OAS1, were lower in the 
cells infected with pLKO-68 and pLKO-72. The relative expression levels were 
shown on a log10 scale. 
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Figure 25 Cell proliferation of the HTB-186 cells infected with pLKO-ctrl, 
pLKO-68 and pLKO-72 lentiviruses. The rate of cell proliferation was slower in 
HTB-186 cells infected with pLKO-68 and pLKO-72 lentiviruses as compared to the 
control pLKO-ctrl.  Results represent means ± SEM (n=3). *Significantly different 
from the corresponding day 1 control (pLKO-ctrl) value, P<0.05. aSignificantly 
different from the corresponding day 2 control (pLKO-ctrl) value, P<0.05. 
















4.3.2 Soft agar assay 
To compare the effects of RUNX3 knockdown on the transformation potential of 
HTB-186 cells, a soft agar colony-formation assay was performed. In HTB-186 cells 
transfected with negative control pLKO-ctrl, many colonies developed (Figure 26a). 
However, the knockdown of RUNX3 with pLKO-68 (Figure 26b) and pLKO-72 
(Figure 26c) significantly reduced the transformation potential of HTB-186. Both 
pLKO-68 and pLKO-72 caused a significant reduction in colony number in vitro, 





Figure 26 Soft agar assay. 7500 transformed cells in 0.3% agarose media were 
added to the 0.5% base agarose in 60 mm dishes and solidified. The plates were 
incubated at 37oC for 5 weeks. Cells were fixed with methanol and stained with 
0.005% crystal violet. Colonies were stained dark blue. (a) Triplicates of plates with 








4.3.3 Nude mice assay  
As shown in Figure 19, HTB-186 cell line expressed endogenous RUNX3. To check 
if RUNX3 acts as an oncogene in DMB cells, two different knockdown of RUNX3 
with lentiviral shRNAs in HTB-186 cell lines expressing reduced amount of RUNX3 
were generated. Although three different cells types were generated, a similar 
percentage of viable cells were injected into each mouse. Interestingly, knockdown of 
endogenous RUNX3 in HTB-186 cells greatly suppress tumorigenicity in nude mice, 
and the tumor suppressive effect was correlated well to the level of RUNX3 
expression in these cell lines. The number of tumors was lower when the level of 
endogenously expressed RUNX3 was lower. pLKO-68 and pLKO-72 developed 
significantly smaller or no tumors when compared to the corresponding pLKO-ctrl 
negative control, P<0.05 (Figure 27). These results show that knockdown of RUNX3 
expression contributes to the tumor suppressive effect in the tumorigenic human 























Figure 27 Nude mice assay with HTB-186 cell lines. HTB-186 cell lines expressing 
various shRNAs were used. HTB-186 cell lines expressing pLKO-68 and pLKO-72 
had highly reduced tumorigenicity in nude mice as compared to control pLKO-ctrl 
cells, indicating the possible role of RUNX3 as an oncogene. NA: no tumor observed. 
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4.4 The RUNX3-SHH interaction is at the level of GLI1 
 
4.4.1 Regulation of RUNX3 by cyclopamine 
Cyclopamine, a major steroidal alkaloid of Veratrum californicum, is an extremely 
potent teratogen in several mammalian species when administered at a specific 
embryonic stage (Keeler 1978). Cyclopamine inhibits the SHH signaling pathway by 
direct binding to SMO (Chen et al 2002). To further confirm that RUNX3 expression 
is regulated by the SHH signaling pathway, experiment in Figure 28 was carried out. 
DMB HTB-186 cells were treated with cyclopamine for various timepoint. When the 
cyclopamine was added to HTB-186 cells, the expression of RUNX3 was gradually 
reduced. Both western blot analysis (Figure 28a) and RT-PCR (Figure 28b) showed a 
time-dependent decreased of RUNX3 expression in HTB-186 cell line upon treatment 
by cyclopamine. This clearly shows that the SHH signaling pathway is involved in the 
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Figure 28 Regulation of RUNX3 by cyclopamine. (a) Immunoblotting of RUNX3 on 
HTB-186 cells after treatment with 10 μM cyclopamine dissolved in DMSO.  Reduction 
of RUNX3 by cyclopamine confirms the involvement of the SHH signaling pathway in 
the regulation of RUNX3 expression. 15 μg of whole cell lysate was loaded per lane. β-
actin was used to normalize the protein loaded in different lanes. DMSO was a vehicle
control. (b) Relative quantification RT-PCR analysis of RUNX3 and GLI1 after 10 μM 
cyclopamine treatment in HTB-186 cell line. The reduced level of GLI indicated that 
SHH signaling pathway was inhibited. The reduced level of RUNX3 protein was
confirmed by RT-PCR. GAPDH was used as the endogenous control to normalize the 
genes. The various timepoints were compared against 0 hr.   
(a) 
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4.4.2 RUNX3 interacts with GLI1 in HTB-186 cells in vitro 
The interactions between endogenously expressed RUNX3 and GLI1 were examined 
in HTB-186 cells. Lysates were analyzed by immunoprecipitation with GLI1 
monoclonal antibody followed by immunoblotting with anti-RUNX3 (5G4) 
monoclonal antibody. The results establish that GLI1 coimmunoprecipitate with 





Figure 29 Detection of endogenous GLI1/RUNX3 complex in HTB-186.  Cell 
lysate (2 mg) was obtained from HTB-186 cells and immunoprecipitated with anti-
GLI1 monoclonal antibody or mouse IgG. Input was 50 µg of pre-cleared cell lysate 
as positive control.  The immunoprecipitate was analyzed by immunoblotting using 






4.4.3 RUNX consensus binding sequences in GLI1 promoter 
Results from Figure 29 shows that RUNX3 is able to form a complex with GLI1 in 
vitro. In order to examine the direct involvement of RUNX3 in the regulation of GLI1 
expression, a human GLI1 promoter was examined. The proposed consensus sequence 
for RUNX binding element was 5’-PuACCPuCA-3’, or in the reverse orientation, 5’-
TG(T/G)GGT-3’, with 5’-AACCACA-3’ being the regular type of sequence found in 
most bona fide RUNX target promoters, and 5’-ACCGCA-3’ being the premium type 
of sequence (Kamachi et al 1990). There were two regular and one premium RUNX 
binding consensus within 800 bp of the GLI1 promoter region and another one 




30a). However, these RUNX binding sites are not conserved in the mouse Gli1 





Figure 30 Promoter region of GLI1. (a) Schematic diagram of the GLI1 promoter, 900 
bp upstream of the transcriptional start site. Four RUNX consensus binding sequence 
were identified. R indicates regular RUNX consensus binding sequence and P indicates 
premium RUNX consensus binding sequence.  (b) Alignment of Human and Mouse GLI1
promoter sequences. The top sequence is from mouse and bottom sequence is from
human GLI1 promoter. RUNX binding sites are not conserved in the mouse Gli1




4.4.4 RUNX3 is recruited to the binding sites on the promoters of GLI1 
To observe if RUNX3 also binds to GLI1 in vitro, ChIP assay was carried out using 
the HTB-186 and CRL-7762 cells containing endogenous RUNX3. As shown in 
Figure 31, the anti-RUNX3 (R3-6E9) monoclonal antibody was able to successfully 
pull down GLI1 promoter region. Quantitation of the ChIP band was done by 
increasing cycles of PCR. PCR using the pull-down DNA by a normal mouse IgG 
acted as negative controls, to show that the pulled-down chromatins by the RUNX3 
antibody was specific. Thus, the results show that RUNX3 binds to the GLI1 
























Site 1 Site 2
Site 2 Site 3
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BCC                       DMB
Input     MIgG 6E9      Input      MIgG 6E9
CRL-7762                 HTB-186
Figure 31 Chromatin immunoprecipitation (ChIP) assay. PCR results with primers 
specific to GLI1 promoter indicates the specificity of pull-down product by anti-RUNX3 
(R3-6E9) monoclonal antibody as well as specificity of antibody used. Mouse IgG
(MIgG) acted as negative controls. 20 ng of purified DNA was amplified with PCR for 
35 cycles. Diagrams on the left panel indicate the targeted sites on GLI1 promoter region. 
PCR for input is done using primers specific to GLI1 promoter. PCR product size: Site 1-





4.4.5 Promoter assay 
In order to examine the direct involvement of RUNX3 in the regulation of GLI1 
expression, a human GLI1 promoter was examined. The constructed promoter 
contains four putative RUNX binding elements (Figure 30). All reporter activity was 
normalized against the luciferase activity expressed by the promoterless pRL-SV40 
vector. Reporter assay was performed using COS-7 cell line (attempts to make this 
promoter assay work for BCC and DMB cell lines were unsatisfactory, presumably 
due to interference with the high level of endogenous RUNX3 and deregulated SHH 
signaling pathway). Figure 32 showed that GLI1 promoter activity was repressed 
when co-transfected with RUNX3 and CBFβ2 in COS-7 cells. Hence, in a non-SHH 
related cell line, RUNX3 is acting as a tumor suppressor, and suppresses the SHH 





Figure 32 GLI reporter assay in COS-7 cell line. All four RUNX consensus binding 
site in GLI1 were cloned and used in this reporter assay.  GLI1 promoter activity was 
down-regulated by co-transfection of RUNX3 and CBFβ2. *Significantly different 
from the corresponding control, P<0.05. 
Site 1 Site 2 Site 3 Site 4
*
  91
CHAPTER 5   DISCUSSIONS  
 
The runt-related (RUNX) family of transcription factors share homology with the 
Drosophila segmentation gene runt and encode the DNA-binding subunit of the 
heterodimeric transcription factor polyomavirus enhancer binding protein 2/core-
binding factor complex (PEBP2/CBF) (van Wijnen et al 2004). RUNX3 was initially 
described as a candidate tumor suppressor in the gastric epithelium and is 
epigenetically silenced in greater than 50% of gastric cancer cell lines (Li et al 2002). 
Li et al had reported fully silenced RUNX3 in 43 of 97 (44%) cases of gastric cancer, 
and subsequently we showed a further 38% functional inactivation by subcellular 
mislocalization in the cytoplasm (Ito et al 2005), therefore suggesting that RUNX3’s 
overall inactivation occurs in around 80% of gastric cancers (Ito et al 2005). Reduced 
or fully obliterated expression of RUNX3 has now been observed in numerous human 
malignancies, including lung cancer (Sato et al 2006, Yanagawa et al 2007), 
glioblastoma (Mueller et al 2007), breast cancer (Lau et al 2006) and bladder cancer 
(Kim et al 2004). Furthermore, RUNX3 point mutations have been discovered in 
human gastric and bladder cancers (Kim et al 2005, Li et al 2002). In all adult solid 
cancers analyzed to date, RUNX3 acts as a tumor suppressor gene (Bae and Choi 2004) 
(down-regulation is associated with tumorigenesis). RUNX3 is frequently inactivated 
by dual mechanisms of protein mislocalization (Ito et al 2005) and promoter 
hypermethylation (Kim et al 2005).   
 
RUNX3 is a relatively new gene discovered in the 1990s (Ito 1999) and has been 
widely studied as a tumor suppressor, but its overall expression and functional roles in 
human pathology are not fully explored. While RUNX3 has been widely studied in 
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various neoplasms, the expression of RUNX3 in skin malignancies and in certain 
neoplasms from the central nervous system was unreported. Our results showed that 
there is universal up-regulation in 2 types of neoplasms with skin appendage origin, 
namely BCC and trichoepithelioma and one histological subtype of medulloblastoma, 
the desmoplastic variant. The analyses showed that RUNX3 proteins in BCC and 
DMB are full length, without structural alteration or mutation, and fully functional.  
 
Many pathways that play an essential role during the embryonic development are 
switched off later in life, during adulthood. The aberrant re-activation of these 
pathways in adult tissue is often oncogenic. The SHH pathway is a good example of 
the kind: while playing a minimal role in most adult tissues, it is known to be 
activated in BCC and medulloblastoma (Oldak et al 2001). Our original observation 
of the coincidence of this unusual RUNX3 overexpression in a small and exclusive 
group of SHH –related malignancies is the core of this thesis. 
 
Similar to the SHH pathway, the wingless-Int (Wnt) and bone morphogenetic 
protein/transforming growth factor-β (BMP/TGF-β) pathways play central 
developmental roles that are conserved from the fruitfly to human (Chen and Meng 
2004, Logan and Nusse 2004). Mutations and deregulation of the Wnt pathway are 
the characteristic features of many human cancers, most notably of intestinal 
malignancies  (Gregorieff and Clevers 2005). Several lines of evidence hint at a role 
for the Wnt pathway in BCC. Firstly, the Wnt pathway is involved in hair follicle 
morphogenesis and its ligands are known targets of SHH signaling (Andl et al 2002, 
Reddy et al 2001). Secondly, the Wnt pathway has been linked to other skin 
malignancies: 75% of human pilomatricoma (another neoplasm that recapitulates a 
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segment of the hair follicle development) cases bear activating mutations of β-catenin 
(Chan et al 1999), and the deregulation of Wnt pathway is linked to the progression of 
human melanomas (Rubinfeld et al 1997, Weeraratna 2005). For these reasons, the 
involvement of Wnt signaling in BCC pathogenesis has been keenly evaluated. Our 
results showed nuclear accumulation of β-catenin in 31 of 75 (41%) BCC tumor 
samples but the expression varied considerably between BCC samples. The frequency 
and subcellular variability at which this occurs indicates that although Wnt signaling 
is involved in the progression of some BCC, it is not likely to be a primary and 
consistent mechanism by which the SHH signal is mediated. In contrast, 
overexpression of RUNX3 in the nucleus of neoplastic cells is observed in all of the 
BCC and DMB samples in the TMA, therefore strongly implicating a role for RUNX3 
as an oncogene downstream of the SHH pathway. This striking observation is made 
all the more significant in view of the current understanding of RUNX3 as a tumor 
suppressor in several human malignancies, most notably in gastric cancer.  
 
Thus, while the RUNX1 and RUNX2 members of the Runt family are known to 
promote tumorigenecity in mouse models (Cameron and Neil 2004, Yanagida et al 
2005), and seem to be overexpressed in malignancies (leukemia and osteosarcoma 
respectively), the putative oncogenic role of RUNX3 is much less clear.  RUNX3 
protein is overexpressed in epithelial ovarian cancer. However, immunohistochemical 
staining revealed a striking difference—the up-regulated RUNX3 in ovarian cancer is 
cytoplasmic (Nevadunsky et al 2009) which, in our opinion, probably represents a 
form of inactivation. Reintroduction of RUNX3 in ovarian cancer cells led to 
increased viability, whereas depletion of RUNX3 resulted in reduced proliferation 
(Nevadunsky et al 2009). RUNX3 also has an oncogenic function in head and neck 
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squamous cell carcinoma in which RUNX3 expression was correlated with enhanced 
cell proliferation and malignancy (Kudo et al 2010, Tsunematsu et al 2009), although 
functional confirmatory in vitro analyses were suboptimal in these studies. In any case, 
these reports may have some form of practical significance: indeed, ectopic RUNX3 
expression inhibited chemotherapeutic drug adriamycin-induced apoptosis in head 
and neck squamous cell carcinoma cells, reminiscent of the RUNX3-induced 
resistance to imatinib-induced apoptosis in chronic myeloid leukemia (Miething et al 
2007, Tsunematsu et al 2009).  
 
In our in vitro work with SHH-related cancers, RUNX3 knockdown resulted in 
significant reduction in cell proliferation. Therefore, RUNX3 may be involved in 
allowing for high cell density, in addition to stimulation of cell growth. Moreover, 
RUNX3 silencing inhibited tumorigenesis in vitro and in vivo, demonstrated by soft 
agar assay and xenografts in nude mice assay. These findings allowed us to 
hypothesize the role of RUNX3 in the malignant behavior and possibly aggressiveness 
of SHH-related neoplasms. The analysis of the gene expression profile in RUNX3 
silenced cells (versus a non-silenced control group) revealed that several genes were 
selectively and concomitantly down-regulated, namely SHH, SMO, PTCH1 and GLI1. 
Thus, while these results suggest a role in proliferation and viability promotion of 
RUNX3, the mechanism is unknown.  
 
The plethora of manuscripts and the increasing interest for RUNX3 in the scientific 
literature is directly related to the increasingly important role of RUNX3 in cancer 
biology. The dual, and to a certain extent contradictory role of RUNX3 as a tumor 
suppressor gene and an oncogene, in a manner that appears to be tissue dependent, 
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announces a complex mode of molecular activation and partnering. This dualistic 
function in cancer (RUNX3 switches between such opposite activities) remains 
unclear and is likely to be of significant biological and perhaps clinical relevance. 
With this in mind, and within the constraints of this thesis, we embarked in the 
analysis of possible partners on SHH-related malignancies. 
 
An important implication of our findings is the early evidence to the possibility of 
cooperation between the SHH pathway and BMP/TGF-β pathways in SHH-related 
neoplasm, which warrants a thorough investigation. It is well established that the SHH 
pathway is modulated via a negative feedback loop through PTCH1, as PTCH1 itself 
is a positive target of GLI3 (Goodrich et al 1996, Marigo et al 1996). In SHH-related 
neoplasms, this intrinsic circuitry control is broken and although the genetics may 
differ, they invariably lead to the constitutive activation of the SHH pathway. 
Importantly, in addition to PTCH1, GLI transcription factors are also known to 
transcriptionally regulate several of the BMPs (Gianakopoulos and Skerjanc 2005, 
Kawai and Sugiura 2001). Whether this then leads to the nuclear accumulation and 
overexpression of RUNX3 in SHH-related neoplasm must now be a subject for 
rigorous examination. If substantiated, then understanding the involvement of 
RUNX3 in SHH-related neoplasm will avail a new avenue of unraveling the complex 
pathogenesis of these common malignancies. 
 
Our work presents evidence that the interaction between RUNX3 and SHH may be at 
the level of GLI1. Briefly, there are four RUNX consensus binding sequences in GLI1 
promoter, and RUNX3 is recruited to the binding sites on the promoters of GLI1. 
Results also showed that RUNX3 is directly involved in the regulation of GLI1 
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expression. In SHH related neoplasms, the silencing of RUNX3 inhibits the SHH 
signaling pathway directly though regulation of GLI1. However, in a non-SHH related 
context, RUNX3 is acting as a tumor suppressor, and suppresses the SHH signaling 
pathway through GLI1.  
 
In general, abnormalities in SHH signaling pathway components that include SHH, 
PTCH1, SMO, GLI1 and GLI2 are major contributing factors in the development of 
SHH-related neoplasm. As discussed earlier, PTCH1 represses SMO signaling. This 
repression is relieved by the binding of SHH to PTCH1 or following the mutational 
inactivation of PTCH1, leading to uncontrolled SMO signaling. PTCH1 itself is a 
target gene of this pathway, and activation of the pathway increases PTCH1 
expression (High and Zedan 2005). We, and others, have observed mRNA 
enhancement in BCCs; however, as this protein is presumably mutated, it remains 
inactive and incapable of inhibiting the SHH pathway (Tang et al 2004). 
 
Added evidence to this interaction is provided by our results with cyclopamine, a 
selective inhibitor of the SHH signaling pathway. Cyclopamine appears to interfere 
with these signaling events by influencing SMO function, as it antagonizes SHH 
pathway activity in a PTCH-independent manner (Taipale et al 2000). In our hands, 
treatment with cyclopamine inhibited the proliferation of HTB-186 cells in a dose- 
and time-dependent manner in vitro, similar to the results of previous reports in other 
types of tumor cells (Berman et al 2003, Feldmann et al 2007). Notably, treatment 
with cyclopamine down-regulated the expression of PTCH1, SMO and GLI1, lead to 
significantly reduced endogenous RUNX3 in vitro. Conceivably, induction of cell 
cycle arrest and apoptosis by the blockage of the SHH signaling pathway suggests 
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that the SHH signaling pathway may act in a similar manner, by promoting cell 
cycling and preventing apoptosis of cells. Therefore, these findings may provide new 
insights into understanding the regulation of the SHH signaling pathway on the 
growth of SHH-related neoplasm. 
 
Although it is well established that deregulation of the SHH pathway plays a central 
role in the molecular pathogenesis of SHH-related neoplasm, the specific targets and 
mechanisms through which tumorigenesis is effected remain elusive. Here we 
propose that a significant player appears to be RUNX3, which interacts with GLI1 in 
vitro. RUNX3 can bind to the promoter region of GLI1, a transcription factor that is 
activated by the SHH signal transduction cascade, and regulate its expression. The 
human GLI1 promoter region is regulated by a 1.4 kb 5’ region including a 5’ 
flanking sequence, an untranslated exon and 425 bp of the first intron. Numerous 
proteins such as Sp1, USF1, USF2, and Twist are also involved in Gli1 promoter 
regulation (Gitelman 1997, Hebrok et al 1997, Villavicencio et al 2002). Some of the 
downstream gene targets of human GLI1 include regulators of the cell cycle and 
apoptosis such as cyclin D2 and plakoglobin respectively (Yoon et al 2002).  
 
Therefore, we propose that GLI1 is a downstream target of RUNX3 and can act as a 
RUNX3-dependent repressor of the SHH signaling pathway which, in turns, allows 
RUNX3 to act as an oncogene in this context (Figure 33). The question as to whether 
this is a one-way effect, or if there is also a possible feedback loop that allows the 
SHH signaling pathway to regulate RUNX3, is central to the understanding of this 










Figure 33 Proposed model of RUNX3 regulation of SHH signaling pathway.  
RUNX3 associates with GLI1, a transcription factor that is activated by the SHH 










CHAPTER 6   CONCLUSIONS AND FUTURE PERSPECTIVE  
 
Our work starts with the interesting observation of selective RUNX3 up-regulation in 
SHH-related malignancies. Further in vitro and functional work allowed us to support, 
for the first time, the unsuspected role of RUNX3 as an oncogene in SHH-related 
neoplasm such as DMB and BCC. Hereby we present evidence to the role of RUNX3 
in the SHH signaling pathway. It is also the first detailed report describing the 
regulation of RUNX3 by SHH signaling pathway. Therefore, a signaling cascade 
involving RUNX3, GLI1 and SHH signaling pathway is proposed.  
 
The possible practical/clinical applications of this model cannot be overemphasized. 
SHH signaling pathway is an important pathway regulating stem cell population in 
skin. This property associated with SHH pathway may be exploited in favor of 
developing novel therapeutics for the treatment of various SHH-related diseases. 
Various compounds targeted to the SHH signaling cascades have been developed but 
without much success. Hence, with these new findings of the role of RUNX3 and its 
interaction with GLI1, a clearer understanding of SHH pathway will be helpful in 
providing successful therapeutic intervention for SHH pathway-dependent neoplasms.   
 
Based on the expression pattern of RUNX3 in the human BCC and DMB samples, 
RUNX3 was expressed in active form. As such, RUNX3 is highly suitable to be used 
as a marker for diagnostic purposes. RUNX3 can be used as part of the diagnostic 
armamentarium of immunohistochemical techniques for the diagnosis of skin cancers 
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SEQUENCE OF HUMAN GLI1 PROMOTER (1000 bp) 
 
































Vector Element  Utility 
Human U6 Promoter RNA generated with four uridine overhangs at each 3' end 
PGK  Phosphoglycerate kinase promoter 
puroR  Puromycin mammalian selectable marker 
SIN LTR  3' Self inactivating long terminal repeat 
f1 ori  f1 origin of replication 
AMPr  Ampicillin bacterial selectable marker 
5'LTR  5' long terminal repeat 
RRE  Rev response element  
 
 
